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Abstract 
Alzheimer’s disease is a neurodegenerative disorder, and the most common form of 
dementia. The disease is becoming increasingly prevalent in our aging population, and 
as there are no effective methods of treating the condition, there is an increasing need 
for the development of new treatments. In this project, the in silico design, screening and 
in vitro validation of a selection of potential type I and type II inhibitors of GSK-3β as a 
possible pathway to a new treatment for Alzheimer’s disease is presented. The screening 
of compounds for possible type I activity was carried out using a newly designed docking 
consensus scoring method, first employing a benchmarking database to assess various 
different combinations of docking algorithms to be used in a virtual screening of 157,238 
compounds. The final consensus scoring method was a Simple Sum Rank combination 
of Glide-SP and –XP, AutoDock Vina and GOLD ASP, chosen based on its superior 
statistical metrics produced for EF (24), EF’ (33) and BEDROC α=160.9 (0.345), all of 
which were higher than those of the individual programs. Pharmacophore models were 
applied to improve the overall accuracy of the results. Once the virtual screening had 
finished 10 diverse final compounds were selected fit for in vitro validation, based on a 
wide variety of different protein-ligand interactions. The best type I inhibitor compound 6 
(ZINC000072152229) with an IC50 of 24.69 ± 0.73 μM. For the investigation of type II 
inhibition of GSK-3β, two different type II DFG-out models were developed for the virtual 
screening of a natural product database (27,286 Compounds). The first model was 
created using DOLPHIN docking, involving the deletion of 5 residues (201-205) to create 
the type II consistent binding site, and the second model was designed using a 
combination of Prime loop refinement, induced fit docking and molecular dynamics. Both 
models were validated using a selection of analogues of type II ligands with known 
experimental inhibition data. Both of the models produced experimentally consistent 
data, which indicated they were both accurate at predicting type II binding. Once the type 
II virtual screening was completed, the resultant ranks of the compounds for each model 
were combined into a simple sum consensus score, and 20 compounds were selected 
for biological validation. The three type II ligands that performed the best in the biological 
validation were Sorafenib (one of the known type II inhibitors) with an IC50 of 32.64 ± 0.76 
µM, compound 2 (ZINC000008299930) with 26.96 ± 1.77 µM and compound 4 
(ZINC000008297322) with 9.75 ± 2.2 µM, a promising result for the first ever screening 
of human GSK-3β for type II inhibition, validating such an approach in the future. 
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Chapter 1: Introduction 
1.1 Introduction to Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common form of dementia, and is becoming 
increasingly prevalent due to advances in modern medicine allowing people to live much 
longer lives[1]. The noncommunicable disease begins in the hippocampus region of the 
brain, and then spreads to the rest of the organ over time[2]. This can manifest itself as 
the decline in thinking ability, motor skills, learning, memory and language skills in 
patients which is caused by the death of neurons, causing severe shrinkage to occur  
(shown in Figure 1.1). 
Figure 1.1: A comparison of a healthy brain (left) and a brain afflicted with Alzheimer’s 
disease (right) displaying severe shrinkage of multiple cortexes caused by the death of 
neurons. [3] 
 The disease was first observed by Alois Alzheimer in 1907, when he described the 
symptoms of a woman who had begun to develop anatomical characteristics that were 
inconsistent with recognised illnesses[4]. This coupled with a rapid loss of memory, and 
the other unusual symptoms the patient displayed, caused Alzheimer to describe the 
disease as a special illness[4]. The patient that Alzheimer had examined had a 
progressive form of presenile dementia4, which would later become known as 
Alzheimer’s disease. AD has two main pathological features that can cause the death of 
neurons, the formation of amyloid plaques, and neurofibrillary tangles[1]. Amyloid 
plaques, also known as senile plaques, are formed by the peptide amyloid beta (Figure 
1.2 (a)) when it appears in the outside of neurons in dense fibrils[1]. This protein is a by-
product of the amyloid precursor protein (APP), which is believed to be involved in 
neuronal development. The other main pathogenic feature of the disease that can cause 
the death of neurons is the formation of neurofibrillary tangles. These tangles are 
aggregated masses of hyperphosphorylated tau protein (Figure 1.2(b)) that accumulate 
as paired helical filaments, and can be expressed in neurons in patients of AD[1]. Tau 
protein acts in the body to stabilize the microtubules in the cytoskeleton of cells1 and is 
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normally regulated by phosphorylation. However, when this process begins to fail, 
hyperphosphorylation starts to occur, beginning the formation of the tangles.  
Figure 1.1: The structures of the two proteins amyloid beta(a) [5] and tau protein(b) [6] 
There is an observed positive correlation between the amount of neurofibrillary tangles 
that are present in the brain and the severity of the dementia caused by AD, which is 
shown in Table 1.1 below[7]. 
Table 1.1: The levels of Hyperphosphorylated tau in patients of senile AD (S AD), 
presenile AD (PS AD) and other dementias (OD). A positive correlation between the 
amount of hyperphosphorylated tau protein and the severity of the dementia can be 
seen. [8] 
Levels of CSF phosphotau (pg/ml) 
S AD 49.78(±36.09) 
SP AD 44.06(±33.29) 
OD 15.01(±27.05) 
 
During Alois Alzheimer’s initial investigation of the brain of the patient in 1907, he 
observed the presence of these two pathological features. In his paper he described 
tangles of fibrils that outlast the neuron itself, as well as small military foci caused by “the 
deposition of a special substance in the cortex”[4], which are the neurofibrillary tangles 
and the amyloid plaques respectively. 
1.2 Symptoms and Diagnosis of Alzheimer’s Disease 
It is well established that subtle cognitive impairment can be displayed in patients years 
before the clinical diagnosis of probable AD[9]. This period, in-between the initial onset of 
the disease and the clinical diagnosis, where the patients begin show these early signs, 
is named the “preclinical phase” [10]. The first suggested sign of AD in clinical literature is 
memory loss for the majority of patients of the disease[11]. Disorientation also appears as 
an early sign of AD, due in part to its relation to the memory loss[11]. Due to the subtlety 
of these symptoms in the early stages, it can be difficult to detect the initial effects. In a 
a 
b 
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study by La Rue et al. [11], they investigated the ease at which different family members 
who accompanied patients to a dementia clinic for a diagnostic evaluation were able to 
detect and notice certain symptoms of the disease in its early stages. The figure below 
(Figure 1.3) shows the symptoms that the family members first recognised for patients 
with dementia of the Alzheimer type (DAT) compared with patients of Multi-Infarct 
dementia (MID) and Depression. 
 Figure 1.3: The first symptoms reported by family members for patients of each of the 
three categories, Depression, DAT and MID[11]. 
As can be seen in Figure 1.3, for DAT, forgetfulness was by far the most common first 
symptom noticed by the family members, with it being spotted in almost 100% of cases. 
The next most common was confusion, spotted in around 50% of cases, and then the 
rest of the symptoms are all clustered around 30%. For MID on the other hand, all other 
symptoms except memory loss were consistently more noticed by family members than 
for AD, however the forgetfulness was observed by just below 90%[11]. In general, 
available literature suggests that the preclinical phase of probable AD can be longer than 
a couple of years[10]. However, because of prohibitive high costs and low yield of 
prospective studies of AD, very few large-scale studies focus on the preclinical phase[10]. 
As a result, the length of the preclinical phase of probable AD, and the signs of onset 
present have not been firmly established[12]. In a paper by McKhann, G et al. [13] they 
outline the symptoms necessary for the diagnosis of Probable, Possible and Definite AD.  
For Probable AD, the patient needs to display deficits in two or more areas of their 
cognition, progressive worsening of their memory functions and an absence of symptoms 
of other brain disorders that could cause the cognitive loss of functions[13]. These 
diagnoses can also be supported by looking for symptoms such as progressive 
deterioration of specific cognitive functions, for example language, perception and motor 
skills. They also could display an impairment of their ability to carry out daily activities, 
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and that their patterns of behaviour have altered[13]. For a diagnosis of definite AD, along 
with the symptoms necessary for probable AD, histopathologic evidence obtained from 
a biopsy is of course also needed[13]. More recently, Paraskevaidi el al [14] recently applied 
NIR (near infra-red) spectroscopy to the detection of the various blood biomarkers of AD, 
and found that their model could differentiate between healthy patients and those with 
AD with an accuracy of 92.8%. 
Prevalence 
According to recent figures from the world health organisation, more than 50 million 
people currently are affected by dementia, including AD [15]. Data obtained from 
population based studies suggests that the prevalence of AD in Europe in people over 
the age of 65 is 4.4%, whereas in the US in over 70s the prevalence is 9.7%[16]. The 
graph below in Figure 1.4, shows the prevalence of AD increases rapidly as the age of 
the patient increases, suggesting that as the population ages, the disease will begin to 
rapidly gain prevalence. It also suggests that people in different areas, for example 
Brazil, can be more likely to have AD at an earlier age. This could be due to multiple 
possible reasons, one example being quality of healthcare. 
Figure 1.4: shows the prevalence of Alzheimer’s disease per 100 people across various 
countries and continents[16]. 
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1.3 Previous and Current Treatments of the Disease 
There have been a few different drugs approved for treating AD throughout the years. 
However, for the most part they are used to alleviate the symptoms of the disease, to 
slow it’s progression in patients, and to try to improve their quality of life. Three common 
types of treatments currently in use, or currently being investigated for combatting AD 
are acetylcholinesterase inhibitors[17], N-Methyl-D-aspartic acid (NMDA) receptor 
antagonists[17] and more recently GSK3-β inhibitors[18]. Neurons in AD have been found 
to express excessive amounts of the neurotransmitter glutamate, which can damage the 
already afflicted neurons further. Therefore prevention of this upregulated action of 
glutamate could serve to slow the progression of the disease that is caused by this 
additional damage[19]. To do this, some of the more frequently prescribed treatments for 
AD, NMDA receptor antagonists, are used to block the receptors that the glutamate 
interacts with. This returns the levels of the neurotransmitter the neuron receives back 
to normal, protects from damage. The National Institute of Health and Care Excellence 
recommends that these treatments are given to patients with moderate to severe 
symptoms, to alleviate the symptoms associated with the later stages of the disease. 
Danysz et al. [20] found that in vivo memantine (shown below in Figure 1.5), a NMDA 
receptor antagonist, provided protection from a variety of neuronal toxic conditions, for 
example the formation of amyloid plaques, inhibition of the mitochondrial function of 
neuronal cell, and inflammation. They then stated that as all three of these factors are 
implicated as pathological features of AD, a drug that can reduce all three should be 
effective as a therapeutic treatment for the disease[20].  
Figure 1.5: The structure of memantine 
The second type of treatment that is used more commonly is acetylcholinesterase 
inhibitors. Through various investigations, it was found that patients of AD have lower 
levels of acetylcholine, a neurotransmitter involved in learning and the encoding of new 
memories[21]. Lower levels of this neurotransmitter has also been linked to the formation 
of amyloid plaques[20] and increases their density, which would cause an increase in the 
progression of neurone death[17]. Therefore, the inhibition of acetylcholinesterase would 
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serve to protect the neurotransmitter from the enzyme, preventing its breakdown and 
therefore raising its levels in the brains of patients. Some examples of different drug 
treatments currently employed that are acetylcholinesterase inhibitors are donepezil 
(Figure 1.6(a)) [22], rivastigmine(Figure 1.6(b)) [23] and galantamine (Figure 1.6(c)) [24]. 
These treatments act to return the levels of the neurotransmitter in the brain to normal, 
restoring the functionality of the neuronal communication, alleviating some of the milder 
symptoms[19].    
 
Figure 1.6: The structures of donepezil (a), rivastigmine (b) and galantamine (c) 
Rogers et al. [22] reported the results of a 15 week, double blind study of the efficacy and 
safety of donepezil in patients with moderate to severe AD. Out of 468 patients, split into 
three groups (placebo, 5 mg/d and 10 mg/d), 56 patients withdrew with adverse effects 
being the most common reason, while the rest finished the trials. They found that patients 
that had received the drug demonstrated improvements in cognitive function superior to 
that of the patients that received the placebo [22]. The clinical improvement of the patients 
in the study are shown below in Figure 1.7. 
a  b 
c 
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Figure 1.7: The least squares mean clinical improvement for cognition each of the 3 
groups of patients with moderate to severe Alzheimer’s disease experienced over a 15 
week period[22]. 
Rosler et al. [23] investigated the acetylcholinesterase inhibitor rivastigmine by testing it 
in an international trial. Similar to the previously mentioned trial of donepezil, the patients 
were separated into three groups (placebo, low dose and high dose). The researchers 
found that by week 26, the difference in mean change in cognitive ability from the 
baseline based on scores on the progressive deterioration scale between the patients 
who took the placebo and those on the higher dose of rivastigmine was statistically 
significant (Figure 1.8). The authors conclude that the study provided evidence that 
Rivastigmine was alleviating the cognitive depreciation associated with moderate to 
severe AD, and that the effects were directly dose dependant[23]. 
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Figure 1.8: The mean change in baseline scores on the cognitive subscale of 
Alzheimer’s disease assessment scale[23]. 
Raskind et al. [24] examined the effects of galantamine in a 6-month double-blind trial with 
patients split into three groups, one with a high dose one with a lower dose and a placebo 
control. This was followed by a 6-month Open label extension where all three groups 
were given the same 24 mg dose, The results of which are shown in Figure 1.9 below[24]. 
Figure 1.9: The mean change from the baseline assessment cognitive subscale scores 
over the first and second 6-month periods[24].  
As can be seen from the graph above, while there is not much difference between the 
results of the two different doses of galantamine, they both show a large increase in 
cognitive function when compared to the placebo. It can also be observed that when the 
placebo group was given its dose at the start of the open-extension period their cognitive 
function improved noticeably. This led the authors to conclude that their study had 
   = 24 mg/24 mg 
   = 32mg/24 mg 
   =  Placebo/24 
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provided evidence that Galantamine helped alleviate some of the symptoms of moderate 
AD in patients[24]. 
Other treatments for this disease include the use of different drugs to combat symptoms, 
for example cerebrolsyn. This drug is a combination of different amino acids and small 
peptides, enzymatically cleaved from purified brain proteins[19]. They act by protecting 
the plasticity of the neurons[25] and protect and support the neurons during stressful 
conditions[26] to slightly improve the mental ability of patients. However, any methods the 
drug uses to exact its therapeutic effects are currently unknown. Some possible 
mechanisms that have been proposed by academic studies and research are 
interactions with the aforementioned amyloid peptides[27], neuroprotective proteins such 
as GSK-3β (glycogen synthase kinase-3) [28], and neurotransmitter receptors[29]. 
1.4 GSK3-β as a target for AD 
While these drugs are being used widely to treat AD, there is a clear need for more 
effective forms of treatment. One such new possible treatment, and the target of this 
project, is the use of inhibitors for the enzyme Glycogen Synthase Kinase-3 beta (GSK-
3β). The enzyme GSK-3β has been found to be a key component in many bodily 
processes and regulation pathways, some examples of this are cell cycle progression 
gene transcription and the insulin signalling cascade [30]. In a paper published in 2007 
called ‘The GSK-3 Hypothesis of Alzheimer’s Disease’[18], the enzyme was linked to the 
pathways of formation of both the amyloid plaques and the neurofibrillary tangles[31]. It 
has also been found that in patients of AD, the enzyme is overexpressed, which is the 
hypothesised cause of the increased β-amyloid production and the hyperphosphorylation 
of the tau protein. It is also associated with local plaque associated microglial-mediated 
inflammatory responses, for example the production of neurotoxic cytokines[32], another 
typical symptom found in disease sufferers, and can lead to the death of neurones. 
1.5 Objectives 
1) To investigate and design novel type I (ATP binding site) and type II (activation loop 
out) inhibitors of GSK-3β. 
2) To apply a consensus scoring method involving a virtual screening with 4 different 
programs, GOLD, Glide-SP, Glide-XP and AutoDock to a large database taken from the 
ZINC docking database website (www.ZINC15.org) [33]. 
3) To design two novel type II structures of GSK-3β, using different computational 
methods, molecular dynamics and DOLPHIN docking[34], and to use them to screen a 
database in silico. The results for these two models are to be combined using a 
consensus scoring method. 
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4) To select the top compounds from both the type I and type II screenings for 
transportation to the CSIC in Madrid on an Erasmus+ placement where they will have 
their IC50 values tested in vitro 
1.6 Synopsis 
While chapter 1 mainly focused on background information about AD, current 
treatments, and the GSK-3β enzyme as a potential target, Chapter 2 of this thesis 
discusses GSK-3β in detail, focusing on the enzyme’s known structural features. It 
describes in detail both of the different types of inhibition used in this project, Type I and 
Type II. Current inhibitors of the ATP binding site of GSK-3β are discussed also. The last 
section of Chapter 2 contains a discussion about inhibitors of Type I GSK-3β that have 
reached clinical trials;  
Chapter 3 presents and describes the theoretical basis behind any computational 
programs and techniques used in this project, beginning with an initial overview of 
molecular modelling. This is followed by a detailed explanation of molecular docking, 
along with a description of any docking programs used and a subsequent description of 
Molecular Dynamics 
Chapter 4 presents the results of this project for Type I inhibition. It begins with a short 
introduction of the topic and the work that I have done with Type I inhibitors. This is 
followed by a detailed explanation of the methodology used including the consensus 
method designed, and the biological experiments carried out at the CSIC. The results of 
each step are then reported and discussed in depth, followed by a conclusion. 
Chapter 5 contains all of the work involving the design of Type II inhibitors and begins 
with a short introduction of the topic. This is followed by a detailed explanation of the 
methodology used in the design of the two different Type II models, the selection of ZINC 
database compounds, the in silico screening and biological validation experiments 
performed. The results of each step are then reported and discussed in depth, followed 
by a conclusion. 
Chapter 6 presents the overall conclusion of the entire project as a whole, as well as an 
analysis of the progression of the project and any suggested future work that could be 
built around this research. 
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Chapter 2: Glycogen Synthase Kinase-3 beta  
2.1 Introduction 
The first reversible inhibitor of GSK-3β discovered was lithium in 1993, by Melton and 
Klein[35]. It was found to act in two different ways, direct inhibition of the enzyme and via 
increasing the inhibitory phosphorylation of the enzyme[31]. When administered, lithium 
was found to reduce the production of both hyperphosphorylated tau[36] and the primary 
component of amyloid plaques, β-amyloid[37]. Additionally, in a recent trial held in Japan, 
it was found to improve the cognitive function of the participants[38]. Unfortunately, lithium 
was found to inhibit many other kinases besides GSK-3β, causing it to have a high 
neurotoxicity due to it affecting the levels of many different neurotransmitters. 
Accordingly, the search for many different, potent and specific inhibitors of GSK-3β has 
continued, and has gained an unsurprisingly large amount of interest[30]. As upwards of 
20 to 30 different crystal structures have been solved for GSK-3β, more and more 
structure based drug design techniques including virtual screening, molecular dynamics, 
and many others being increasingly employed in the search for new inhibitors that are 
more selective than lithium.  
2.2 Structural features of GSK-3β 
Like all other proteins, the structures of enzymes are incredibly important in relation to 
the functions that they carry out, and also how they interact with other molecules in the 
body. Therefore, knowledge about the structures of these enzymes is crucial for the 
study and design of potential inhibitors. GSK-3, a multifunctional Ser/Thr kinase, has 
many different roles in the human body and various diseases, including AD [39]. Currently, 
there are only two known members of the mammalian GSK-3 family, GSK-3α and GSK-
3β. In this project, we will focus on the β form. The structure of GSK-3β consists of a 
coupled pair of domains, a carboxy-terminal α-helical domain and an amino-terminal β-
sheet domain, which is shown below in Figure 2.1[40]. 
Figure 2.1: GSK-3β, the amino-terminal end of the enzyme (residue 35) is shown in blue 
and the carboxy-terminal end (residue 384) is shown in red [40]. 
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GSK-3β has a molecular weight of 47 kDa is made up of 420 amino acid residues, 
however only 351 (35 to 386) have shown any clear electron density when studied[40]. 
Unusually, unlike most other similar kinases, the visible N terminal-β-sheet domain end 
of GSK-3β (residues 35-134) consists of a closed orthogonal β barrel formed from a 
seven-stranded β-sheet. Moreover, between residues 4 and 104, the 5th and 6th strands 
of the β-sheet are connected by a small α-helix, which is shorter than that of other 
kinases, with only 2 turns. After the N terminal section, the residues between 138 and 
149 form an α helix connecting the N terminal section to the rest of the molecule. 
Residues 152 to to 342, form the main section of the α-helical domain, similar to that of 
some MAP (mitogen activated protein) kinases[41]. One major difference however, is the 
absence of a second α-helical domain located between residues 276 and 293[42].  The 
next noteworthy structural feature appears between residues 342 and 386 in the form of 
a series of short loops and helices, pressed against the long helix located between 
residues 155 and 175. This feature, unlike the α-helical domain, is atypical compared to 
most other MAP kinases, as this region would normally snake back and re-join the N 
terminal end of the enzyme[40]. The other end of the protein, the C terminal, begins at 
residue 384. GSK-3β has a pair of phosphorylation sites, the first being residue Ser9, 
the phosphorylation site for AKT (another Ser/Thr kinase) and the second being residue 
Tyr216, which increases the catalytic activity of the enzyme[43]. It also has an Axin binding 
channel (Axin being a protein with importance in the Wnt signalling pathway), located 
between residues 262 and 273, that is formed by an α-helix[44]. 
2.3 ATP binding site 
GSK-3β, like all other kinases, uses ATP molecules to phosphorylate substrate 
molecules, and to activate the kinase activity that takes place in its active site. Therefore, 
the ATP binding site is located in the cleft between the N-terminal domain and the C-
terminal domain, inside the “activation segment” of the active site of the enzyme [45]. 
When this Tyr216 is phosphorylated, it creates a conformation of the activation segment 
that correctly forms and aligns the catalytic and substrate binding sites, largely increasing 
enzymatic activity[45]. When ATP enters the binding site, the enzyme removes one of its 
phosphate groups and transfers it to either a threonine or serine residue of the enzyme’s 
various substrates[46]. Another important region of the ATP binding site is the hinge 
region. This region, containing the residues Asp133, Tyr134 and Val135 is very important 
for the binding of inhibitor molecules to the ATP binding site[45][47][42]. The ATP binding 
site also contains the activation loop, or DFG loop (Asp200-Phe201-Gly202). This loop 
can have two formations, the DFG-in active conformation where the phenyl sidechain of 
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the phenylalanine residue is positioned on the inside of the loop, and the DFG-out 
inactive conformation, where the phenyl group is flipped outside the loop[48].  
Inhibition of the ATP binding site of a kinase with the activation loop in the DFG–in 
conformation is known as Type I inhibition[48]. This is the most commonly explored type 
of inhibition for most kinases, including GSK-3 β, due to the fact that it mostly acts by 
substrate phosphorylation from the ATP binding site. The first groups of molecules with 
already known inhibitory activity against other kinases to be tested against GSK-3β were 
the paullones, indirubines and bisindol-malemides[31][49]. All of these compounds were 
shown to be competitive with ATP for its binding site. Some well-known and studied type 
I inhibitors are shown in Figure 2.2, along with their inhibition data.  
 
Figure 2.2: Three well known inhibitors of GSK-3β, 1) 6BIO (5 nM), 2) alsterpaullone 
(0.8 nM) and 3) staurosporine (15 nM) 
While inhibition of the ATP binding site is the most straightforward way to inhibit a kinase, 
it is ATP competitive, which as discussed in chapter one may have kinase selectivity 
problems. One of the earlier groups of ATP binding site inhibitors discovered for GSK-
3β are the derivatives of the malemide family of compounds. In the complex of GSK-3β 
with a malemide derivative, shown below in Figure 2.3, two hydrogen bond interactions 
are formed with the hinge region, one from the NH of the malemide derivative to the 
carbonyl oxygen of the backbone of Asp133, and the other between the adjacent 
carbonyl on the inhibitor to the backbone NH of Val135[47]. The IC50 values for the 
malemide compounds range between 4nM and 34nM, making them strongly potent 
inhibitors. Two other hydrogen bond interactions can be observed, with Arg141 and 
Gln185, which can serve to hold the inhibitor in place. 
1 
2 3 
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Figure 2.3: The complex between GSK-3β and a malemide derivative bound at the ATP 
binding site [47] 
A second example of an ATP competitive type I inhibitor is staurosporine, a natural 
molecule synthesised by the bacterium Streptomyces staurosporeus [50]. The interactions 
it forms with the ATP binding site are very similar to those formed by the malemides, as 
it forms two hydrogen bond interactions with the hinge region, one with the Asp133 
carbonyl and one with the Val135 NH. While these are the only direct bonds the molecule 
forms with the site, it has also been reported to have polar interactions as well[45]. The 
reported IC50 value for staurosporine was of 15 nM [51], making it as equally potent as the 
malemides. A third group of molecules that inhibit GSK-3β at the ATP binding site are 
the paullones[52]. One example from this family of compounds is 9-nitro-paullone, more 
commonly known as alsterpaullone, shown below in complex with GSK-3β (Figure 2.4). 
These compound are some of the most potent inhibitors of GSK-3β to have been found 
to date, with the IC50 of alsterpaullone being 0.8 nm[53], and it has been observed that 
derivatisation can increase its potency by a magnitude of up to 150 times[47]. 
Alsterpaullone can be seen to also form two hydrogen bond interactions with the hinge 
region; however, these are both formed with Val135, one to its backbone carbonyl and 
one with the backbone NH, as well as a polar interaction with the sidechain of Lys85. 
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 Figure 2.4: Alsterpaullone (in yellow), interacting with the ATP binding site of GSK-3β 
[47]. 
Another family of derivatives that can inhibit GSK-3β in a type I manner are the indoles[47], 
a group of compounds made from naturally occurring indigo dyes. One good example of 
a subgroup of this family that show strong inhibition are the indirubins. 6-bromoindirubin-
3-oxime, more commonly known as 6-BIO (shown in complex with GSK-3β in Figure 
2.5), has an IC50 of 5nM[42].  
Figure 2.5: The structure of 6-bromoindirubin-3-oxime interacting with the ATP binding 
site of GSK-3β [47] 
6-BIO interacts with the ATP binding site similarly to the previous molecules. It has the 
interaction between a NH on one of its rings with the backbone carbonyl of Asp133, and 
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the carbonyl oxygen on the same ring of the inhibitor interacts via a hydrogen bond with 
the NH of Val135. The NH of the other fused ring system of 6-BIO also interacts with 
Val135 via hydrogen bonding, this time with the backbone carbonyl. Once again, this 
strong binding molecule displays multiple hinge region interactions, which serves to 
explain why these interactions are highly sought in the design of new inhibitors, and why 
binding to this region has been explored in great depth. Another group of inhibitors of 
GSK-3β are the oxidiazole derivatives, the best of which has an IC50 of around 2.3 nM[54]. 
These compounds were also found to be selective for GSK-3β, an uncommon trait for 
ATP binding site inhibitors to have. They also bind by forming two hydrogen bonds with 
Val135, but they also form a unique hydrogen bond relay network between the nitrogen 
atoms of the oxidiazole, Lys85, Glu97 and Asp200 via two water molecules [47]. 
2.4 Overview of Type II Inhibition in Kinases 
This section presents a brief overview of the general features for type II inhibition in 
kinases, whereas the next section will specifically address the features for GSK-3β .Type 
II inhibition involves the binding of inhibitors to the enzyme while the activation loop is in 
the DFG-out position. This allows the inhibitor to extend past the loop from the ATP 
binding site into the allosteric site that is opened by the removal of the phenyl group of 
the phenylalanine from its entrance [48]. This flipping of the loop is shown below in Figure 
2.6. 
Figure 2.6: A comparison of a DFG-out conformation (left) and a DFG-in conformation 
(right)[48]. The inactive conformation of a kinase is produced by the DFG-F out position, 
and this will be referred to as DFG out in the rest of this thesis. 
As can be seen from the figure above, the backbone of the DFG loop rotates, flipping 
the side chain of the phenylalanine outside of the loop and opening up the entrance to 
the allosteric site cavity, whereas the side chain of the aspartic acid is flipped inside. 
Importantly, this does not restrict the entrance to the cavity, as the ASP sidechain is 
much smaller than the phenyl ring, and is tucked more towards the side of the pocket. 
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The rotation of the backbone also positions the backbone NH of the aspartic acid close 
to the entrance of the pocket, which creates a site for a hydrogen bond interaction. This 
interaction with the backbone NH is actually one of the classical interactions of a type II 
complex[34] along with one or two hydrogen bonds with the glutamic acid of the αC-helix 
and a hydrogen bond with the hinge region. These interactions are shown below in 
Figure 2.7. As well as these three interactions, another important factor in a kinases 
ability to form a type II complex is the gatekeeper residue[48]. This residue, if too large, 
can block the space between the hinge and the allosteric pocket that the hinge end part 
of the inhibitor would occupy, preventing the molecule from binding in that region, which 
as previously discussed is an important interaction for type II inhibitors. 
Figure 2.7: The ligand BIRB-796 (ball and stick molecule) docked into a complex in a 
type II conformation, with the classical interactions displayed[34]. 
It is hypothesised that type II inhibitors have the potential to be much more selective than 
type I, owing to the uniqueness of inactive kinase conformations[48]. The first FDA 
approved type II inhibitor was a molecule named imatinib[55]. It is used to inhibit ABL 
Kinase for the treatment of Philadelphia-positive chronic myeloid leukaemia (Ph+CML). 
Imatinib displays all three classical type II interactions, and even an advantageous 
hydrogen bond with the side chain of the Thr315 gatekeeper residue[48]. Another type II 
inhibitor that has achieved FDA approval is sorafenib[48][56]. The molecule is an inhibitor 
of multiple protein kinases, including CDK8 serine/threonine kinases and is currently 
treatment of hepatocellular, renal cell, and differentiated thyroid carcinomas. As 
sorafenib binds to the inactive conformation, it also forms all of the classical interactions 
expected of a type II inhibitor, however, in this case the two NH urea groups of Sorafenib 
can exploit two hydrogen bonds with the αC glutamic acid. A third and final example of 
a type II inhibitor is nilotinib[48]. Nilotinib is also an inhibitor of ABL, for the treatment of 
Ph+CML, and was developed as a second-line medication for CML that has become 
imatinib resistant through mutations. It has a similar core structure to imatinib, and 
therefore shares its 3 classical hydrogen bond interactions, as well as the hydrogen bond 
with the gatekeeper residue[48]. Nilotinib is effective against most mutant versions of ABL, 
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the biggest exclusion to this being the common T351 gatekeeper mutation to isoleucine, 
a residue bulky enough to block type II activity. 
2.5 Type II of GSK3-β Inhibition 
While type II inhibition could prove highly selective and therefore much more specialised 
than type I inhibition, it has not yet been proven that this type of inhibition can occur for 
GSK-3β. However, a paper by Grütter et al[56] showed the Ustilago Maydis form of GSK-
3β undergoes type II inhibition with analogues of the previously mentioned known type 
II inhibitors, sorafenib and BIRB-796. The structures of these two inhibitors are shown 
below in Figure 2.8.  
Figure 2.8: The structure of BIRB-796 (above) and sorafenib (below), known type II 
inhibitors. 
As well as this, the paper also showed the analogues of these two compounds having 
activity, although lower, with the human form of the enzyme with an IC50 of 8.1 mM. This 
could be evidence that the human form can also transition to a DFG-out conformation 
and therefore undergo type II inhibition. If this is the case, combined with the gatekeeper 
residue of GSK-3β being Leu132, a relatively small residue that would not block type II 
activity, then there is the potential for the design of novel type II inhibitors to be used as 
treatments for AD. If possible, these would be have the potential to be much more 
selective than ATP binding site inhibitors that are much more commonly investigated for 
the enzyme. The biggest difference between the human form and the Ustilago Maydis 
form around the area containing the DFG loop is that the former contains a salt bridge 
between the residues Gln206, Phe175 and Lys103[56] shown below in Figure 2.9. As this 
is the only real difference in this area, it is possible that the reason the type II inhibitors 
received a lower IC50 with the human form due to the salt bridge needing to be broken 
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before the loop can enter the DFG-out conformation. The IC50 values for the derivatives 
of sorafenib are shown below in Figure 2.10, which clearly display that the general shape 
of a these compounds is conducive to type II interaction. 
Figure 2.9: The salt bridge formed in the human GSK-3β(blue), super imposed on the 
Ustilago Maydis Form(green)[56]. 
 
Compound IC50 UMGSK3 IC50 HsGSK3β 
Sorafenib 0.71± 0.21 8.3 ± 0.8 
16 (sorafenib derivative) 0.057 ± 0.011 0.86 ± 0.18 
17 (sorafenib derivative) 0.154 ± 0.103 3.3 ± 0.6 
Figure 2.10: The structures of the sorafenib derivatives and their IC50 values with both 
forms of GSK-3β[56]. 
Sorafenib 
Sorafenib Derivatives 
16 
 
 
 
17 
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2.6 GSK-3β Inhibitors in clinical trials 
Before new treatments can be administered to, and distributed among, the general 
public, they must successfully undergo clinical trials, which typically involve 3 phases (1-
3), but can have up to 4, (0-4). Phase 0 and Phase 1 trials tests small doses the drug on 
minimal selections of people, to investigate and responses that occur in the bodies of 
the participants, any side effects that may occur, and the range for safe doses. Phase 2 
trials are more focused on administering the drug to larger groups of people to further 
investigate the optimization of the dosage of the drug necessary for the best therapeutic 
effect. Drugs that pass this stage progress to the next phase of trials, phase 3, which is 
used to compare the therapeutic effects achieved with the new drug treatment to those 
of other treatments that are currently available. If the drugs then pass phase 3 trials may 
then be moved on to the phase 4 trials, which are performed after a drug has been given 
a licence, are carried out to observe any long term effects the drugs might have, and 
how well it works when it is used more widely. Due to the current academic interest in 
the use of GSK-3 β inhibitors to combat AD, a number of these inhibitors have now 
reached human clinical trials. One example of an inhibitor of GSK-3 β involved in a 
clinical trial is a 2 phase trial titled “Safety Study of a Glycogen Synthase Kinase 3 
(GSK3) Inhibitor in Patients with AD” [57]. The trial aimed to determine the safest oral 
dose of NP031112, a GSK-3β inhibitor (Figure 2.11), for patients with mild to moderate 
AD [57]. The trial took a selection of males and females aged between 60-85, and 
administered either four escalating oral doses of the drug or a placebo, to investigate 
any side effects. As of the September 2018, Clinical trials.gov [58] and the World Health 
Organisation [57] have not received the results from this trial, however, it is stated that the 
trial has ended on both websites. In a second example, the GSK-3β inhibitor AZD1080 
(Figure 2.11), reached phase one clinical trials in 2013 [59]. However, as these trials 
proved unsuccessful, they were eventually were discontinued and discarded[60]. The first 
group of none ATP competitive inhibitors of GSK-3β to be found were the 
thiadiazolidinones [61] and since their discovery many other non ATP inhibitors have also 
been found. Through studies the thiadiazolidinones were shown to decrease levels of 
tau hyperphosphorylation and amyloid plaques, with a second generation 
thiadiazolidinone family drug recently reaching clinical trials, showing that these 
compounds have great promise as inhibitors for the enzyme[62]. There are many differing 
derivatives of the thiadiazolidinones, for example TDZD-8 (Figure 2.11), which are still 
being synthesised and modified to test their inhibitory activity, and the family of molecules 
has remained largely relevant in the field of GSK-3β inhibition and AD research. 
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Figure 2.11: Drugs used in some of the aforementioned clinical trials: A is TDZD-8, a 
derivative of thiadiazolidinone and a known selective inhibitor of GSK-3β. [63] Drug B is 
NP031112 [64], C is lithium carbonate [65] and D is AZD1080 [66]. 
 Another example of a clinical trial involving an inhibitor of GSK-3 β is a 3 phase trial titled 
“Evaluation of Lithium as a Glycogen-Synthase-Kinase-3 (GSK-3) Inhibitor in Mild 
Cognitive Impairment” [67]. This trial aims to create information designed to justify a much 
larger study of lithium as a GSK-3 β inhibitor, as well as technical data for use in Magnetic 
Resonance Spectroscopy (MRS) with the aim of detecting early brain changes in patients 
of AD. The secondary objective of the study, is to investigate if blood amounts of GSK-3 
relate to GSK-3 activity in the brain[64]. According to the description, the first phase of the 
trial, rats will be used to help create a reliable method to measure the brain biomarker 
activity levels. In phase 2 of the trial, they intend to investigate the difference in GSK-3 β 
activity between people with AD and people without the disease. In the third and final 
phase of the trial, lithium carbonate (Figure 2.10) will be administered to 20 people to 
establish the minimum dose required to inhibit the activity of GSK-3 β [67]. As of 
September 2018, this trial has not begun recruiting participants. An American company 
ChemDiv [68] published an online library called GSK3β-Targeted Library. In the literature 
[39] they provide alongside this library, a table (p9-10 [39]) with examples of GSK-3 β 
inhibitors currently undergoing clinical trials. One example from the table is LY-2090314, 
which moved into phase 2 trials, with a good clearance time, however the creators of the 
drug did not report its therapeutic effects [46]. Another example shown in the table [39] is 
indirubin, which was produced by the Chinese Academy of Sciences and was entering 
clinical trials as the paper [39] was produced. A final inhibitor that made it into trials is 
tideglusib, which advanced to stage 2 trials and is one of the more widely known 
inhibitors that made it to clinical trials, however, it was found in multiple trials to have no 
long term clinical benefit, despite it being safe to take [69]. 
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2.7 Conclusion 
As can be seen in this chapter, the type I inhibition of GSK-3β has been explored in great 
depth, meaning that there is a lot of data available that can greatly aid researchers in the 
hunt for new, potent and selective inhibitor molecules. However, to date virtually none of 
the GSK-3β inhibitors trialled have successfully passed through clinical trials, meaning 
that there is still more work needed in this area in terms of potential treatments for 
Alzheimer’s disease. Type II on the other-hand, a much less common form of inhibition, 
is entirely novel and unexplored with GSK-3β, and a breakthrough in this area of 
research could potentially lead to much more selective inhibitors. 
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Chapter 3: Molecular Modelling 
3.1 Introduction 
Molecular modelling techniques have become an integral and important part of many 
research areas. A rapid increase in prevalence can be in part attributed to advancements 
in software and hardware that can be used by researchers, as new computational 
techniques are constantly being developed [70]. These advances have enabled 
researchers to more easily carry out a plethora of complex simulations, calculations and 
predictions, allowing them to study, for example, complex biological structures in depth. 
As well as this, there has been a considerable increase in accessible structural data for 
enzymes and other proteins (www.pdb.org), through NMR, X-ray crystallography and 
electron microscope studies [70] (Figure 3.1). This structural data can then be used to 
predict many possible interactions that the proteins could have, as well as structure 
based drug design (SBDD) efforts and it has led to computational techniques to 
becoming more widely used.  
Figure 3.1: GSK-3β solved with x-ray crystallography [71] (PDB: 2OW3). The larger ligand 
shown is 2OW3, the smaller ligand indicates the location of the allosteric binding site. 
One of the most widely used techniques that uses molecular modelling is virtual 
screening. This technique involves the use of use of a variety of docking programs, which 
will be discussed in depth in Section 3.2, and other computational procedures to screen 
a large database of organic molecules for any compounds that show possible activity 
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with a certain protein [72]. The initial step of a virtual screening is the design a 
computational screening method that can recognise and select already known active 
compounds from a large database that contains both known active compounds and 
decoy molecules similar in structure to the active compounds. Once developed, this 
method can then be used to screen large databases, selecting any compounds with 
scores similar to those of the actives used to create the method to be investigated in a 
lab study. 
This chapter will give a brief overview of some common techniques used, with an 
emphasis on methods relevant to this thesis. 
3.2 Biological Structure Prediction and Analysis 
One of the most common applications in molecular modelling currently is the 
investigation of large biological molecules and their structures. There are more than 
40511 distinct protein sequences available[73], and the amount of sequenced genomes 
growing exponentially. While it would take inordinately long amounts of research time to 
even begin to sort through all of this structural data manually, all of the recent 
technological advances and new computational techniques allow for the data to be fully 
processed quickly and easily. This means any generated information can be effectively 
incorporated in hypothesis driven biological research, as well as medicinal chemistry 
research [70].  
Sequence analysis is one example of a technique that can be used to investigate 
biological structures. The structure and amino acid sequences of a protein have great 
importance in relation to its function. For example, using the hydrophobicity of an amino 
acid in a sequence, its location and orientation can be discerned using sequence 
analysis [70]. From this positional information, a secondary structure can be predicted. 
This is useful for finding 3D structural features, for example structural folds, by comparing 
the secondary structure with that of other similar proteins, as obtaining of a 3D structure 
is extremely helpful for the researchers that use molecular modelling techniques. There 
are quite a few varied molecular modelling techniques that can be used to find the 3D 
structures of proteins. A first example of this is threading [70], which threads the sequence 
through a database, trying all the possible conformations while scoring them. Another 
technique is Ab initio modelling [75], which involves using statistical analysis and energy 
functions based on physics to predict any possible folds for newly acquired sequences. 
A third technique, homology modelling [74], uses homologues, a type of structural 
template, which must be chosen after thorough analysis. These produced models can 
then, during structure validation, be analysed further, to produce a Z score to show if the 
structure is accurate [70]. Homologues must also be validated as it would be would be 
useful to compare them. 
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3.3 Pharmacophore and QSAR Methods 
Another example of a type of molecular modelling technique that is regularly employed 
in drug design is pharmacophore modelling. Pharmacophore modelling is mainly used 
to find molecules with similar structural features to a known active for an enzyme. This 
involves the creation of a set of pharmacophore templates, which are created using a 
selection of known active compounds, mapping the geometric locations of their functional 
groups that form interactions, and then comparing the geometry of different molecules 
to find any that have similar groups in the same areas [76]. Groups that can be used when 
creating pharmacophore templates are Hydrogen Bond Acceptors (HBAs), Hydrogen 
Bond Donors (HBDs), and large VdW force exerting groups, like aromatics.  
Molecular modelling can also be used to make predictions for the various drug like 
properties of small organic molecules using QSAR and 3D QSAR. QSAR, which stands 
for Quantitative Structure Activity Relationship [77], is used to relate any structural and 
physiochemical features of a small organic molecule to its interactive activity, in a 
predicted mathematical fashion. The main physiochemical properties that can be used 
to calculate the potentials for biological activity are; the hydrophobicity of the molecule 
and its substituents and the electronic properties and steric properties of the 
substituents[78]. The equation used for this is the Hansch equation, which is shown in 
Equation 3.1. C and LogP are the molar concentration and the hydrophobicity 
respectively, π covers the steric factors and σ involves any electronic factors 
𝐿𝑜𝑔
1
𝐶
=  −0.015(𝑙𝑜𝑔𝑃2) + 0.14 𝑙𝑜𝑔𝑃                    Eq. 3.1 
+0.27 ∑ π𝑥 + 0.40 ∑ π𝑦 + 0.65 ∑ σ𝑥 + 0.88 ∑ σ𝑦 + 2.34 
On the other hand, 3D QSAR employs the use of pharmacophore models to help predict 
possible biological activity, and does this by positioning both the molecule and the 
pharmacophore into a three dimensional grid. At each point of this grid a probe atom is 
placed, and this probe atom is used to measure any possible steric and electronic 
interactions that the molecule can have at that point in the 3D grid. This information is 
then used to create a 3D interaction model that can then be used to predict the biological 
activity of the molecule using regular QSAR. 
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3.4 Molecular mechanics 
A further important aspect of molecular modelling is the use of molecular mechanics. 
Molecular mechanics potentials are used in molecular modelling to determine the forces 
acting on atoms in the calculation in the form of forcefields. These forcefields can be 
used to predict values for 2 classes of interactions, non-bonded interactions, for example 
van der Waals forces and bonded interactions, for example bond angle bending, bond 
stretching and bond torsion. Each of the different interactions has their own term in the 
full equation for a forcefield, an example of which is shown below in equation 3.2 [70]. 
 
 
Eq. 3.2 
 
 
Where, for the bonds term; kd is the force constant of the bond, d is the bond length, d0 
is the reference bond length. This term is used to simulate and calculate the potential 
bond-lengths for a molecule. For the angles term, which predicts the angles of all of the 
molecules’ bonds ((a) Figure 3.2), kθ is the force constant of the bond angle, θ is the size 
of the predicted bond angle and θ0 is the reference angle size. For the prediction of the 
angles of dihedrals in a molecule ((b) Figure 3.2), the dihedrals term is used, in which A 
is the summation coefficient, π is the torsional angle, n is the multiplicity of the function 
and ϕ is the phase shift. Non bonded interactions, both the columbic interactions 
(charges) and atoms terms, are shown between pairs of atoms (i and j). In these terms; 
qi is the partial atomic charge for atom i, ε is the coulombic potential, C is the Van der 
Waals radius multiplied by the Lennard-Jones well-depth, r is the distance between 2 
atoms.  
Figure 3.2: 3 diagrams related to the equation above (Eq. 3.2). In this figure: (a) visually 
represents θ in the angles term, (b) represents π in the dihedral term and (c) displays a 
graph of a Lennard jones potential. 
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The atoms term calculates the relationship between the attractive and repulsive energies 
that the simulated molecule experiences through the calculation of a Lennard Jones 
potential ((c) Figure 3.2). This is done by plotting the bonding potential energy against 
distance of separation for two atoms or molecules based on the Pauli repulsion energies, 
a summation of the repulsive forces acting on the particles, and the summation of the 
Van der Waals forces acting on the particles when they are moved closer together. When 
the molecules are too far apart to affect each other the potential energy between them 
is 0, this increases as they get closer. At the point at which the two particles are close 
enough to bind together, the potential energy decreases to a negative value, until they 
reach equilibrium and the minimum potential energy is achieved. However when these 
molecules are pushed even closer, the repulsive forces begin to exact a stronger effect, 
and the potential energy rises again sharply. As the distance is plotted starting from 0, 
the effects of the repulsion on the potential energy, and then the lessening of the effects 
are seen in reverse, which creates the Lennard-Jones function. 
3.5 Docking Methods 
Another of the more prevalent uses of molecular modelling techniques, and the one 
being used the most in this project, is molecular docking. Docking is mainly used in the 
prediction and ranking of binding affinities (and binding geometry) for ligands, drugs and 
other small molecule compounds with protein complexes, but is not limited to such [70]. 
Docking programs have two main parts, a search algorithm and an energy scoring 
function [79]. A search algorithm is the mathematical equation with which a docking 
program searches for conformations of ligand molecules and their subsequent docking 
poses. Currently there are 2 main search algorithm classes that are regularly used by 
modern docking programs, and these are rigid and flexible docking. Used mainly by older 
programs, for example DOCK, rigid docking treats the ligand as a rigid structure meaning 
that the conformations for the ligands are generated before the docking begins, and then 
docked separately into the protein to create the poses [80]. On the other hand, flexible 
docking treats the ligand as flexible, generating ligand conformations once the ligand is 
already inside the active site “on the fly” while the docking is taking place. This allows it 
to avoid using conformations that do not fit into the site while taking into account the 
geometry of the protein, and allows more exhaustive searching for the best conformation 
[80]. Flexible docking is the most common type of search algorithm used today, and has 
subtypes of its own. The first major example of a type of a flexible docking search 
algorithm is a Genetic algorithm, a diagram of which is shown in Figure 3.3. Genetic 
algorithms use Darwinian evolution to search for the best ligand binding conformations, 
which means a set of conformations in the binding site first, and the best interactive 
features these different conformations have are then combined to generate a “child” 
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generation of conformations. These new conformations may then be randomly mutated, 
making changes to certain features. This is then repeated until there is no significant 
improvement in the score produced by the next generation of conformations.  
Figure 3.3: A diagram showing the processes used in a Genetic search algorithm [81] 
An example of a program that uses this type of algorithm is GOLD [82] which is a product 
of the Cambridge Crystallographic Data Centre (CCDC), and is also one of the more 
commonly used docking programs. GOLD uses a Genetic flexible search algorithm, and 
it also offers a wide variety of scoring functions, example being Chemscore and 
ChemPLP, which are empirical based scoring functions, ASP, a knowledge based 
scoring function and Goldscore, a force field based scoring function. This range of 
scoring functions allows for the researcher to use a variety of different methods when 
investigating ligand molecules within the same program. While the GUI was found to be 
a little bare, the wizard provided for setting up docking calculations greatly increases the 
ease at which GOLD can be used. In one paper, D. Kitchen et al [82] investigated the 
accuracy of GOLD and found that the ligand poses it produced compare well with the X-
ray conformations, stating that any poses that were produced were satisfactory and 
comparable to those produced by other competitor programs such as Glide. 
Another type of flexible docking search algorithm commonly used today is called a 
hierarchical search algorithm shown in Figure 3.4. In this type of search algorithm, 
individual ligand features are selected and filtered one at a time, for example its diameter, 
how well it can rotate around its diameter in the active site, its ability to make H-bonds 
and other similar features. Once these filters have been applied, the search algorithm 
minimizes the ligand, rescoring it using the full scoring function. This type of algorithm is 
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used by Schrödinger’s Glide [83]. Glide, a commercial docking program created by the 
company Schrödinger, is arguably the most popular docking program currently in use, 
and is incorporated into the GUI Maestro [84]. Glide uses a flexible docking hierarchical 
search algorithm, and the scoring functions it uses, standard-precision (SP) and extra-
precision (XP) are empirical based scoring functions. One study about Glide docking 
claimed the software was almost twice as accurate as other available docking programs 
[85]. Its GUI is intuitive and easier to use than many other similarly advanced and 
specialised software, and due to never releasing its exact details, their search algorithm 
is unique. 
Critical to the accuracy of docking programs is the scoring function. This is used by the 
program to score the ligands’ poses, and there are 3 main types [86]. The first type is an 
Empirical scoring function, some examples in use today being -SP/-XP with Glide and 
ChemPLP with GOLD. This type of scoring function acts by parameterising the ligand 
binding mode against documented experimental binding affinities, incorporating 
important interactions such as H-bonding, lipophilic interactions, ionic interactions and 
any loss of internal conformational freedom experienced by the ligand [87]. A knowledge 
based scoring function is the second type, one example being ASP. These score ligands 
based on statistical analysis of known interactions. The final common type of scoring 
function is a force-field based scoring function, which is based on the values obtained by 
molecular mechanics force fields like those discussed in Section 3.4. Examples of 
programs that use this type of scoring function are AutoDock and DOCK. 
Figure 3.4: A diagram showing the processes used in a Hierarchical search algorithm. 
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3.6 Molecular Dynamics 
Molecular Dynamics (MD) simulations, including the aforementioned molecular 
mechanics, can be used to simulate a chemical system over time, and to accurately 
calculate macroscopic properties of these systems, in an attempt to surpass current 
technological restrictions. This sometimes done via the creation of a simulation cell. 
Simulation cells are an orthorhombic box, or in the case of this project cubic, around the 
simulation system containing solvent molecules, and therefore cannot accurately 
represent the bulk properties of a real solvent liquid. This is overcome through the 
introduction of periodic boundary conditions (PBC), in which if an atom leaves the cell 
through its right side, it will enter at the same time through the left (Figure 3.5). 
Figure 3.5: A 2 dimensional system with periodic boundary conditions, with the centre 
box being replicated multiple times to form an infinite lattice. 
Statistical mechanics is employed in these simulations to link macroscopic and 
microscopic properties, and it does so by constraining certain parameters in the 
macroscopic state, the trajectory of the space points will move on a surface of phase 
space. The constraint parameters that control the thermodynamic state of the 
macroscopic system define this surface. According to ergodic theorem [88], this works 
with the assumption that, in a system time will follow a trajectory, eventually visiting all 
microscopic states consistent with the imposed external constraints. This fundamental 
concept of the ergodic theorem gives us a connection between the macroscopic 
property, G and the time average of this property over all microscopic states, Gt, which 
is shown in the equation below; 
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𝐺 =  𝐺𝑡 =  〈𝐺𝑖〉𝑡𝑖𝑚𝑒 =  
1
𝑀
∑ 𝐺𝑖
𝑀
𝑡=1    Eq. 3.3 
In this equation, Gi is the value of the ith state, and M is the number of states. When a 
system is in equilibrium, Gi fluctuates around the equilibrium value, 〈𝐺𝑖〉. This 
instantaneous fluctuation 𝛿𝐺, at time t is described using the equation; 
𝛿𝐺𝑖(𝑡) =  𝐺𝑖(𝑡) −  〈𝐺𝑖〉    Eq. 3.4 
 
The general concept of MD is the solving of the classical Newton’s equations for motion 
of a system of atoms interacting, according to the potential energy forcefields, as 
discussed previously with molecular mechanics. As with earlier, these forcefields work 
with the idea that the solution for the equations of motion of a molecule represent the 
time evolution of the trajectory, again with Newton’s law of motion: 
?⃗?𝑖 = 𝑚𝑖?⃗?𝑖    Eq. 3.5 
where Fi is the force, m is the mass and a is the acceleration of atom i. This equation can 
be integrated numerically, allowing for the prediction of where these atoms will move 
over a short period of time. By repeating this process in succession, the full time 
dependant trajectory can be created for the whole system which represents the 
molecular motions. The main advantage of MD over molecular mechanics is that it does 
not restrict the system to harmonic motion around a single minima, but instead allows for 
the crossing of energy maxima to explore other stable conformations of the system. 
This solving of the law of motion (Eq. 3.5) can be computed directly as a derivative of 
the potential energy V, with respect to the atomic coordinates ri, using the equation 
shown below: 
−
𝜕𝑉
𝜕𝑟𝑖
= 𝑚𝑖
𝜕2𝑟𝑖⃗⃗⃗ ⃗
𝜕𝑡2
   Eq. 3.6 
Then, from this equation, the force acting on atom i can be obtained. The standard 
numerical method for the solving of this equation for future positions is the finite 
difference method, by expressing the motion of a particular particle can be expressed in 
a Taylor series. 
If the position at time t is written as 𝑟 ⃗⃗⃗(𝑡)then the position of the particle after a short 
interval of time, the (timestop) 𝛿𝑡 is: 
𝑟(𝑡 + 𝛿𝑡) = 𝑟 ⃗⃗⃗(𝑡) +
𝜕𝑟
𝜕𝑡
𝛿𝑡 +
𝜕2𝑟𝑖⃗⃗⃗ ⃗
𝜕𝑡2
𝛿𝑡2
2
+ 𝑜(𝛿𝑡3) Eq. 3.7 
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The terms in this equation stand for; the position 𝑟 ⃗⃗⃗(𝑡), the velocity 
𝜕𝑟
𝜕𝑡
 and the 
acceleration 
𝜕2𝑟𝑖⃗⃗⃗ ⃗
𝜕𝑡2
. Knowledge of the values of these three parameters is needed for the 
calculation. The general process of a dynamics calculation is carried out as follows; 
 The input coordinates  𝑟 ⃗⃗⃗(𝑡 = 0)are required, and the initial velocities and 
acceleration are obtained from the potential energy equation. 
 𝑟 ⃗⃗⃗(𝑡 + 𝛿𝑡) is then estimated and new coordinates are obtained 
 The equation then updates the velocity and acceleration values 
This process is repeated until the simulation is complete. In molecular dynamics, the 
integration algorithms that can be used to solve the motion equation can be based 
around the Leapfrog Verlet scheme[89], which comes with a variety of ensembles, for 
example NPT and NVT. 
3.7 Conclusion 
As seen throughout this chapter, there are a multitude of different applications for 
molecular modelling in chemistry, the investigation of biological and organic molecules 
and drug design. It is little surprise, therefore, that many researchers in medicinal 
chemistry are turning to these methods to speed up and aid with selection of new 
possible hit and lead compounds. The range of pharmacokinetics and 
pharmacodynamics data able to be predicted with computational calculations, and the 
speed and inexpensive way by which they can be calculated, make them almost 
indispensable in the search for new treatments for various diseases. Also, due to the 
large selection of different programs tackling similar processes in a different manner, a 
good example of this being the different search algorithms and scoring functions of the 
different docking software, and this allows different methods to be compared, to find the 
best one for a particular project. As also discussed in Section 3.1, the resources available 
to researchers are ever increasing and improving, with the databases that can be used 
holding hundreds of millions of compounds, and with thousands of freely accessible 
solved protein structures. In conclusion computational chemistry is a vital asset and 
provides more targeted grounds on which to build new research. It will also serve to 
speed up the drug design process exponentially as advancements in all fields continue, 
especially in projects such as the current. 
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Chapter 4: In Silico Screening and Experimental Validation of GSK-3β Type I 
Inhibitors 
4.1 Introduction 
Alzheimer’s disease (AD) is a neurodegenerative disease characterised by a loss of 
memory ability and cognitive function. This is caused in part by the formation of 
pathological features, mainly amyloid plaques and neurofibrillary tangles that cause the 
death of neurons. The progressive death of neurons causes the lobes of the brain in a 
sufferer of AD to shrink, triggering the decline in function. In 2007, Hooper et al. [18] 
published a paper called ‘The GSK-3 Hypothesis of Alzheimer’s Disease’, which 
contained a summary of all the evidence implicating the over action of the enzyme 
Glycogen Synthase Kinase-3 beta (GSK-3β), a Ser/Thr kinase, in the formation 
pathways of both the amyloid plaques and the neurofibrillary tangles. Therefore, the 
inhibition of GSK-3β could serve to reduce the formation of the two pathological features, 
potentially providing a new form of effective treatment for AD that is sorely needed. The 
most common way that a kinase of this type is inhibited is through type I ATP binding 
site inhibition, as all kinases use ATP to enact their functions. Therefore, while not 
necessarily highly selective, ATP competitive inhibitors have the potential to be highly 
potent and selectivity has previously been achieved[90]. The ATP binding site of GSK-3β 
is located in the cleft between the N-terminal β-sheet domain and the C-terminal α-helical 
domain of the enzyme, and area called the “activation segment”. In this chapter, we 
present the screening of large database of compounds for type I inhibitory activity with 
GSK-3β, and the biological validation of the results. For the design of the virtual 
screening, a series of benchmarking studies using a designed training set of ligands, 
containing 30 known active inhibitors and 2089 inactive and decoy inactive molecules, 
were used to develop a reliable consensus scoring method for the virtual screening. This 
was done using multiple programs Glide-SP and -XP, GOLD[91] and Autodock[92]. This 
consensus method was then applied to the large database of compounds that was 
obtained from the ZINC15[33] database, and the virtual screening was carried out. Upon 
the completion of the virtual screening, a selection of sorting methods, including 
consensus binding based sorting methods and pharmacophores were investigated for 
use in the selection of compounds from the results of the screening for biological 
validation. The final selected molecules were taken to the Consejo Superior De 
Investigaciones Cientificas (CSIC) the Spanish national research institute, for in vitro 
validation binding assays of enzyme inhibition. 
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4.2 Aim 
To design and implement a consensus scoring in silico virtual screening method for the 
selection of novel type I inhibitors of the enzyme GSK-3β from a large database of drug-
like biological molecules for the possible treatment of Alzheimer’s disease. Biological 
screening of selected compounds. 
4.2.1 Specific Objectives 
 Benchmarking study: to design an in silico method combining the results of 
multiple docking programs using a consensus scoring method 
 To apply the screening protocol to a downloaded database of ZINC purchasable 
compounds to screen for potential activity with GSK-3β 
 To select a set of compounds from the results of the in silico screening for 
purchase following further analysis of their binding potential 
 To validate the results of the virtual screening using biological in vitro assays for 
the purchased compounds 
4.3 Computational methods 
4.3.1 Creation of an Active/Decoy Ligand Set 
The active and inactive ligands used in the benchmarking study were all extracted from 
the ChEMBL[93] database (www.ebi.ac.uk/chembl)[94]. This is a chemical database fully 
available to the public containing bioactive molecules with drug-like properties. The best 
range of ligands with known binding affinities to select the active compounds from was 
determined using their IC50 (1-50 nM, 432 compounds) and inhibitory constant (Ki) values 
(1-50 nM, 143 molecules). These molecules were then prepared with Schrödinger`s 
LigPrep[95], converting their 2D structures to 3D based on stereochemical, tautomeric 
and ionization variations[94]. The forcefield used for the minimization was the OPLS3 
(Harder et al.[422]) forcefield, as it is to date the most accurate and covers the chemical 
space in the most comprehensive manner[96]. After this, the ionisation states of the 
ligands were then generated with possible states at target pH 6 to 8, with the chiralities 
set to be determined using the 3D structure. [94] 
In total 576 ligands were downloaded, which were then clustered. The representatives 
of these clusters would form the final `actives` that will be employed throughout the 
benchmarking docking calculations. The software used to cluster the ligands was 
Schrödinger`s Canvas[97] using a DISE (directed sphere exclusion) diversity based 
selection method. The type of binary fingerprint of the structures selected for use was 
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‘radial’. The size of the subset of clusters was set to 30, producing a set of 30 structurally 
diverse active ligands for use in the active/decoy benchmarking study. [94] 
Once the set of 30 active ligands was obtained, the next step was the generation of 
decoys (presumed inactives), performed using the DUD-E decoy generator[98] [94]. The 
generator acts by processing the selected active compounds, and then outputting a 
maximum of 50 compounds with similar, each having similar physico-chemical properties 
but with dissimilar 2D topology.[99] Similarly to the active and inactive ligands, the decoys 
also needed preparation with LigPrep before use (using the same settings as described 
above). [94] The final database contained the 30 known active ligands shown in Table 4.1 
below, along with 189 real inactive molecules (from ChEMBL with IC50 and Ki’s > 50 μM), 
and the 1900 DUD-E decoys that were generated. The total number of molecules 
including tautomeric/ionization states was 3102 ligand structures. [94] 
Table 4.1: The 30 active molecules obtained from ChEMBL[94] together with their GSK-
3β inhibition data 
 
Entr
y No. 
2D Active Ligand Structure 
Scaffold 
Type 
Ki/IC50 
Affinit
y  
(nM) 
Reference 
1 
 
CHEMBL388978 
 
 
 
 
 
Staurosporine 
 
IC50 = 
15 nM 
 
 
 
 
Ki = 22 
nM 
 
 
Eur. J. Med. 
Chem., 
(2009) 
44:6:2361 
 
 
Bioorg. Med. 
Chem. Lett., 
(2010) 
20:5:1661 
2 
 
CHEMBL1087499 
 
 
 
 
Maleimide 
 
 
 
 
IC50 = 
3 nM 
 
 
 
 
Bioorg Med 
Chem Lett 
2007; 17: 
2863-8. 
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3 
 
CHEMBL215803 
 
 
 
Quinoxalinone 
-2-one 
 
Macrocyclic 
 
 
 
IC50 = 
13 nM 
 
 
 
Bioorg. Med. 
Chem. Lett., 
(2006) 
16:19:5122 
4 
 
CHEMBL2443026 
 
Isoxazole 
 
IC50 = 
10 nM 
 
Bioorg. Med. 
Chem., 
(2013) 
21:22:7047 
5 
 
CHEMBL65987 
 
 
Pyrimidine 
 
Pyrazole 
 
 
IC50 = 
7.94 
nM 
 
 
Bioorg. Med. 
Chem. Lett., 
(2004) 
14:9:2121 
6 
 
CHEMBL3125370 
 
 
 
6-
bromoindirubin
-3 
-oxime 
 
 
 
IC50 = 
5 nM 
 
 
 
Bioorg. Med. 
Chem. Lett., 
(2014) 
24:6:1532 
7 
 
CHEMBL3085387 
 
 
 
Oxadiazole 
 
 
 
IC50 = 
2.5 nM 
 
 
 
Bioorg. Med. 
Chem., 
(2008) 
16:2:636 
8 
 
 
 
Amino-
pyrazole 
 
 
 
 
Bioorg. Med. 
Chem., 
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CHEMBL1684800 IC50 = 
2.73 
nM 
(2011) 
19:6:1915 
9 
 
CHEMBL1940907 
 
 
Quinolone 
 
 
IC50 = 
10 nM 
 
 
Bioorg. Med. 
Chem., 
(2012) 
20:3:1188 
10 
 
CHEMBL317657 
 
 
Pyrazolo-
pyridine 
 
 
IC50 = 
14 nM 
 
 
J. Med. 
Chem., 
(2008) 
51:7:2062 
11 
 
CHEMBL562089 
 
 
 
Benzimidazole 
 
 
 
IC50 = 
40 nM 
 
 
 
Eur. J. Med. 
Chem., 
(2009) 
44:6:2361 
12 
 
CHEMBL362155 
 
 
Pyrazolo- 
Pyridazine 
 
 
 
Ki = 50 
nM 
 
 
J. Med. 
Chem., 
(2004) 
47:19:4716 
13 
 
CHEMBL380946 
 
Pyrazole 
 
IC50 = 
50 nM 
 
Bioorg. Med. 
Chem. Lett., 
(2006) 
16:4:1084 
14 
 
 
 
 
Pyrazolone 
 
 
 
Ki = 
0.22 
nM 
 
 
 
J. Med. 
Chem., 
(2012) 
55:21:9107 
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CHEMBL2177173d 
15 
 
3I4Be 
 
 
 
Pyrimidyl 
Pyrole 
 
 
 
IC50 = 
29 nM 
 
 
 
J Med Chem 
2009; 52: 
6362-8. 
16 
 
CHEMBL1086735 
 
 
 
Pyrazolone 
 
 
 
Ki = 3 
nM 
 
 
 
Bioorg. Med. 
Chem. Lett., 
(2010) 
20:5:1661 
17 
  
CHEMBL1099297 
 
 
 
Amino-furazan 
 
(Oxadiazole) 
 
 
 
IC50 = 
41 nM 
 
 
 
Bioorg. Med. 
Chem. Lett., 
(2009) 
19:5:1508 
18 
 
CHEMBL3091543 
 
Pyrimidone 
 
IC50 = 
6.5 nM 
 
Bioorg. Med. 
Chem. Lett., 
(2013) 
23:24:6933 
19 
  
CHEMBL402902 
 
 
Pyrimidine 
 
 
IC50 = 
3 nM 
 
 
Bioorg. Med. 
Chem. Lett., 
(2008) 
18:12:3578 
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20 
 
CHEMBL2048675 
 
Imidazo-
pyridine 
 
IC50 = 
30 nM 
 
Bioorg. Med. 
Chem. Lett., 
(2012) 
22:13:4221 
21 
 
CHEMBL2386093 
 
 
Maleimide 
 
 
IC50 = 
0.53 
nM 
 
 
J. Med. 
Chem., 
(2013) 
56:12:5115 
22 
 
CHEMBL270473 
 
Benzimidazole 
 
IC50 = 
1.5 nM 
 
Bioorg. Med. 
Chem., 
(2008) 
16:2:636 
23 
 
CHEMBL311228 
 
 
Purine 
 
 
IC50 = 
30 nM 
 
 
Proc. Natl. 
Acad. Sci. 
U.S.A., 
(2007) 
104:51:2052
3 
24 
 
CHEMBL361708 
 
 
 
Hymenialdisine 
 
Paullone 
 
 
 
 
IC50 = 
10 nM 
 
Eur. J. Med. 
Chem., 
(2009) 
44:6:2361 
 
Trends 
Pharmacol. 
Sci., (2004) 
25:9:471 
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25 
 
CHEMBL1092754 
 
 
Benzofuranone 
 
 
IC50 = 
5.9 nM 
 
 
Bioorg. Med. 
Chem. Lett., 
(2010) 
20:7:2321 
26 
 
CHEMBL472043 
 
 
Oxadiazole 
 
 
IC50 = 
8.6 nM 
 
 
Bioorg. Med. 
Chem., 
(2009) 
17:5:2017 
27 
 
CHEMBL2071201 
 
 
 
Pyrimidine 
 
Pyrazole 
 
 
 
IC50 = 
34 nM 
 
 
 
Bioorg. Med. 
Chem. Lett., 
(2012) 
22:14:4750 
28 
 
CHEMBL255735 
 
 
Azapurine 
 
Pyrimidine 
 
 
IC50 = 
7 nM 
 
 
Bioorg. Med. 
Chem. Lett., 
(2008) 
18:12:3578 
29 
 
 
 
Pyrimidine 
 
 
IC50 = 
30 nM 
 
 
Bioorg. Med. 
Chem. Lett., 
(2008) 
18:2:653 
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CHEMBL403405 
30 
 
CHEMBL412142 
 
 
Pyrimidine 
 
 
 
IC50 = 
7 nM 
 
 
Trends 
Pharmacol. 
Sci., (2004) 
25:9:471 
 
 
4.3.2 Creation of the In Silico Screening Database 
The full preparation of the database for the in silico screening, in terms of processes 
applied and the amounts of compounds left after each step is summarised below in 
Figure 4.1. The tool used to obtain the initial compounds library for the actual virtual 
screening was the tranche browser of ZINC15 [33] (www.ZINC15.org), which allows the 
user to filter the entire ZINC database based on chemical properties such as molecular 
weight and LogP. The subset of compounds selected was the “drug like” subset, which 
contained a total of 123,547,009 compounds, defined by a molecular weight range of 
200-500 Da, and LogP values between -1 and 5. [100] We increased the maximum 
molecular weight of the compounds to be downloaded to include the above 500 Da 
section, as there are known inhibitors of GSK-3β above this molecular weight and also 
because we planned to subsequently apply our own filters for maximum molecular weight 
and other properties. This increased the total to 123,557,117 ligands, downloaded in .smi 
format. [100] 
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Figure 4.1: The creation of the benchmarking database, including the ligand counts at 
each step 
With the resources available here, this number of ligands is far too large to be screened 
in a reasonable time period. Therefore, the shuffle command (c.f. appendix), was used 
to obtain a selection of 500,000 diverse ligands from the downloaded compounds to be 
imported for the 3D minimization. [100] As the SMILES all contained defined chiralities, 
they were imported into Schrödinger’s Canvas [101] and then converted to 3D structures. 
These were then minimized using MacroModel [102] For the MacroModel minimization, 
the force field employed was OPLS3[100], as this was used in the preparation of the 
benchmarking database[94]. The method used for the minimization was the Truncated 
Newton Conjugate Gradient (TCNG), and the maximum iterations used was 300. All 
other settings were left as default. [100] 
QikProp[103] from Schrödinger was used for ADME (Absorption, Distribution, Metabolism, 
Elimination) properties predictions allowing us to further sort and filter the ligands in the 
screening database. All settings for this were left as default. Filter rules were mainly 
based on Lipinski’s rule of 5 [104], as well as [100] another paper containing 
recommendations for increasing a drugs blood-brain barrier permeability by Ghose et al. 
[105] The filter rules are shown below 
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 Molecular weight ≥ 200 and ≤ 650. This was based on Lipinski’s rule of 5, 
increased to 650 to incorporate the full molecular weight range of the 30 known 
actives. 
 LogP O/W between and including 0 and 5. This too was based on the rule of 5, 
and left unmodified. 
 The amount of Hydrogen Bond Acceptors (HBAs) on the molecule ≥ 0 and ≤ 10, 
also from Lipinski’s rules. This was already applied by the drug like subset with 
which it was downloaded. 
 The amount of Hydrogen Bond Donors (HBDs) on the molecule ≥ 0 and ≤ 5. 
Similarly to the HBA’s, this was both applied during the download from ZINC and 
also part of Lipinski’s rules. 
 The number of rotatable bonds must be less than or equal to 8. Included from 
Verbers Parameters [106] and modified on the recommendations of Ghose et al. 
 A predicted CNS of 0 or above. This parameter was taken straight from the 
recommendations of Ghose et al[105], but modified to include compounds with a 
CNS of 0. 
These filters were applied leaving 157,238 compounds. The filtered compounds were 
then prepared using Schrödinger’s LigPrep, using the same settings as those of the 
benchmarking database[100] producing 202856 compounds including tautomers and 
ionisation states. 
4.3.3 Protein Preparation for Docking 
The PDB selected for docking was 2OW3 (Figure 4.2). This selection was based of the 
work of Doerksen [107] and collaborators in which they docked 24 diverse ligands into 13 
different crystal structures of GSK-3β. 2OW3 was the PDB that recovered the highest 
percentage of actives, and therefore was chosen for this project. The preparation of the 
protein was carried out using Schrödinger`s Protein Preparation Wizard. Water 
molecules more than 5Å from het groups were removed, and, the bond orders were 
assigned and all missing hydrogen atoms were added [94]. The system was then refined 
using a restrained minimisation with the OPLS3 forcefield, with heavy atom convergence 
set to an RMSD of 0.3 Å to remove steric clashes.[94] The rest of the water molecules 
were then removed for subsequent docking. The co-crystalised ligand was modified to a 
pH of 7.0 ± 3.0, to generate a tautomer with the lowest state penalty. 
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Figure 4.2: The 3D structure of the 2OW3 PDB, with a 2D structure of the bis-
(indole)malemide pyridinophane inhibitor used to solve the crystal structure which can 
also be seen in the 3D model (circled in red). 
4.3.4 Glide Docking Details 
During docking, the shape and properties of the protein are mapped onto a grid with co-
ordinates (X= -36.94, Y=-2.52, Z=69.5), that contains several sets of fields to accurately 
score ligands. This grid was generated using Glide`s Receptor Grid Generation feature. 
[94] The crystal ligand structure that was already bound within the ATP binding site used 
as the centre of the grid. In both the Glide-SP and -XP docking calculations, OPLS3 was 
used as the forcefield, the van der Waals radii factor was left at 0.80 and partial charge 
cut off was left at 0.15. Nitrogen inversion sampling, flexible ligand sampling and the 
sampling of ring conformations including input ring conformations were all also selected. 
For results output after the calculation, post docking minimization was selected to 
minimise the produced poses, minimising the ligand within the receptor field and allowing 
for more accurate poses. Strain correction terms were also selected, to optimise each 
ligand pose produced. [100]. Ligands were ranked by Glidescore, with one pose saved per 
ligand 
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4.3.5 GOLD Docking Details 
The protein, taken directly from the previous protein preparation calculations (4.3.3), was 
selected in the GOLD wizard, the centroid of the co-crystallised ligand was used to define 
the site. Then, the distance from this centre point in which atoms can be selected to 
make interactions with the docked ligands was set to 10 Å. After this the detect cavity 
setting was also used, which restricts the selection of atoms for interactions to the solvent 
accessible surface of the site. Force all H bond donors/acceptors to be treated as solvent 
accessible was also selected. The search efficiency was set to 100% for all of the scoring 
functions, as this is the default setting. The ligands were also selected unmodified from 
Maestro, in .mol2 format. For the output, GOLD was set to only keep the best solution 
for each ligand [100]. GOLD calculations were initially performed using the ChemPLP 
and ASP scoring functions. 
4.3.6 Autodock Docking Details 
The ligand files were converted to .sdf in Maestro, for use in Autodock (version 4.2). [94] 
This is done using the chemical toolbox `Open Babel`. As .sdf files store the structures 
in 2D, energy minimisations were performed to acquire 3D structures. One of the 
parameters used for this is the Universal Force Field (UFF), which contains parameters 
for every atom. Another is a conjugate gradient optimisation algorithm. The number of 
minimisation steps used was set to 200. [94] The files were then converted to the .pdbqt 
format. This file format is able to store partial charges, atomic coordinates and AutoDock 
receptor and ligand atom types [94]. The unedited protein structure can be imported to 
PyRx (the GUI for Autodock), where it is instantly converted to the .pdbqt format. The 
co-ordinates and search space dimensions (Å) were obtained from the glide grid 
generated for docking [94]. The docking algorithm selected for use was the Lamarckian 
Algorithm (LA), as it was the most accurate algorithm available[94]. 
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4.3.7 Consensus scoring 
As consensus scoring can be used to potentially vastly increase the accuracy of a virtual 
screening[72], two main types of consensus scoring involving the ranks produced by each 
program were investigated. These were: 
 Simple sum rank consensus scoring. The simple sum rank is obtained by 
calculating the sum of all the ranks obtained from all the programs, giving an 
overall consensus rank.  
i.e.: (Glide ranks + GOLD Ranks + AutoDock ranks) = Ligand Simple Sum 
Rank 
 Deprecated sum ranked consensus scoring. This form of consensus scoring is 
initially the same as the simple sum rank, however, the worst scoring rank for 
each ligand is removed for the equation before the consensus rank is calculated. 
i.e.: (Glide ranks + GOLD ranks + AutoDock ranks) – Worst Score = Ligand 
Deprecated Sum Rank 
As each docking program used did not score and return every ligand in the database, 
with some ligands rejected due to structural problems or other computational issues, a 
method was needed to match each of the ranks from the four different programs with 
their identifier codes into a single database. This was done using the KNIME analytics 
platform. KNIME uses a workflow of editable nodes as a replacement for code, allowing 
the user to perform similar data processing tasks without the need for knowledge of the 
intricacies of any coding languages. As well as this, it also contains nodes that can be 
edited using python, allowing for more complex coding to be included. The results of 
each of the screenings were exported from Maestro in the form of .csv files. The data 
from the .csv files for each docking method were sorted using the workflow shown in 
Figure 4.3 below. The data for each .csv file is first read by the csv reader nodes, which 
then pass the data to the column filter nodes, which select the columns that are needed. 
This data is then combined with the data of the previous .csv files using the joiner node, 
and finally the compounds missing a value are all given the highest rank for the 
respective program. This was then all written to a final consensus .csv file. KNIME was 
found to be extremely effective and intuitive and could be very easily applied to future 
screening projects as well. 
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Figure 4.3: The KNIME workflow used to merge the .csv files containing the results from  
each of the docking programs into the final consensus score. 
4.3.8 Statistical Analysis of Performance 
Once the various docking calculations were finished and results imported into Maestro, 
they were then sorted by their scores to obtain ranks. For GOLD, the higher the fitness 
rating the better, and for Glide and Autodock the lower the score the better. The best 
score each ligand received was retained considering the tautomeric and ionisation 
states. Some statistical parameters that provide a much clearer view of the results of the 
docking performance were then calculated using the post process Enrichment Calculator 
available in Maestro[100], more specifically: 
 The Enrichment Factor (EF): measures the Number of actives recovered in a 
database, relating the how many were recovered in the subset to the amount in 
the whole database. The enrichment factor is calculated using the following 
equation: 
𝑬𝑭𝑿% =
𝒏𝒂÷𝑵𝒙%
𝒏
𝑵
   Eq. 4.1 
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EFx% is the enrichment factor, (na) is the amount of actives received in a subset 
and (Nx%) is the subset size. (n) is the total number of actives and N is the total 
number of compounds in the database. 
 
 The modified enrichment factor (EF’): not only measures the number of actives 
recovered in a certain subset of the database, but how early they were returned 
in that subset The equation used for the calculation of EF’ is: 
𝐄𝐅′ =
𝟓𝟎%/𝐀𝐏𝐑𝐚
𝐧𝐚÷𝐍𝐱%
   Eq. 4.2 
APRa is the average percentage rank of the number of actives recovered. All 
other values are the same as in the EF equation  
 
 The Receiver Operator Characteristic (ROC): a measure of the accuracy of a 
docking program that can be plotted, producing a curve. The area under the ROC 
plot curve, or AU-ROC, indicates the probability of a random active molecule to 
appear in the earlier subsets of a database than a random decoy molecule. The 
equation for the this is: 
𝐀𝐔 − 𝐑𝐎𝐂 = 𝟏 −
∑ 𝐫𝐢
𝐧
𝐢=𝟏
𝐧(𝐍−𝐧)
+
𝐧+𝟏
𝟐(𝐍−𝐧)
  Eq. 4.3 
In this equation, n is the number of actives, N is the total number of compounds 
in the database and ri is the rank of the ith active 
 
 The Boltzmann-Enhanced Discrimination Receiver Operator Characteristic 
(BEDROC): uses an exponential decay function allowing the reduction of the 
influence of lower ranked compounds on the overall score. The equation for this 
is: 
𝐁𝐄𝐃𝐑𝐎𝐂 = 𝐑𝐈𝐄 ×
𝟏
𝐍
𝐬𝐢𝐧𝐡(
𝛂
𝟐
)
𝐜𝐨𝐬𝐡(
𝛂
𝟐
)−𝐜𝐨𝐬𝐡(
𝛂
𝟐
−𝛂
𝐧
𝐍
)
+
𝟏
𝟏−𝐞
𝛂(
𝐍−𝐧
𝐍
)
 Eq. 4.4 
Where n is the number of actives, N is the total number of compounds, the α 
parameter provides the definition of the early recognition problem. For example, 
if the value for the α parameter is 20, it would cause 80% of the final BEDROC 
score to be taken from the first 8% of the ranks in the data set. 
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4.3.9 Design of Pharmacophore Models 
Ligand based pharmacophore modelling calculations were performed using Phase [v4.5] 
[111] The first models were generated from the 30 actives and 189 inactives from the 
active/decoy ligand set, and the second set of models was developed using a selection 
of 17 crystal structure from Doerksen et al [77]. Conformations for each of these ligands 
were either generated using ConfGen 2.8 with “thorough sampling” exploiting 
MacroModel 10.4 or else taken directly (unchanged) from crystallized protein complexes, 
as described in the results. Solvation effects were included using the generalized 
Born/surface area (GB/SA) model for water. A threshold value of 10 kcal/mol above the 
global minimum conformation was used for saving structures, with a RMSD value (heavy 
atoms) of ≤ 1.0 Å used to eliminate redundant conformations.  
The Survival Score defines how well active compounds are mapped onto a 
pharmacophore and it also provides an overall ranking of the hypotheses. Contribution 
to the ranking of the hypotheses includes the quality of alignment, which comprises of 
three parameters: the site score, vector score and the volume score. Survival Scores 
were also generated for our inactive molecules which allowed us to generate a new 
score, by subtracting the inactive survival score from the active survival score. 
4.4 Experimental details 
4.4.1 In Vitro testing of GSK-3β activity 
All chemicals were obtained from Sigma Aldrich (Poole, Dorset, UK) unless stated 
otherwise. 
The compounds selected were then tested in vitro at the Centro de Investigaciones 
Biologicas (CIB) in Madrid. The CIB is a part of the Consejo Superior de Investigaciones 
Cientificas, the public research centre in Spain and the third largest research institute in 
Europe. Two different tests were performed, a kinase inhibition assay to ascertain which 
of the compounds were inhibitors, and then an IC50 assay to determine the potency of 
the kinase inhibitor. 
4.4.2 Luminosity assay for percentage inhibition 
The GSK-3β enzyme (Millipore, UK) was stored as 10μg in MilliQ water (100μg/mL) a 
concentration10x stronger than needed and the enzyme was then stored at 80°C. On 
the day of the experiment, the enzyme was thawed and kept on ice prior to use and 
diluted to a working concentration of (22.72ng/10μl). The GSK-3β activity was assayed 
in a buffer solution, the components of which are shown in Table 4.2 below.  
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Table 4.2: A table of the various components that make up the Kinase Buffer solution 
used in the kinetics assays. (A): DDT was initially added to the buffer, but was found not 
only to be none essential to the reaction, but to also block the effects of some inhibitors, 
and was therefore removed. 
Compound Stock (dilution) Final Conc Volumes for 20ml 
KB 
HEPES 500mM (10x) 50mM 2ml 
EGTA 50mM (50x) 1Mm 0.4ml 
EDTA 500mM (500x) 1mM 0.04ml 
Magnesium acetate 1M (67x) 15mM 0.3ml 
BSA 2mg/ml-1 0.1mg/ml-1 1ml 
DDT (A) 10mM (10x) 1mM 2ml 
MiliQ water - - 14.26ml 
Total - - 20ml 
 
The substrate used in this assay was GS2 (phospho-glycogen synthase kinase peptide-
2 (Millipore)) which has the amino acid sequence:  
Y R R A A V P P S P S L S R H S S P H Q (PS) E D E E E.  
This substrate was diluted to a working concentration of 100 μM. ATP (Sigma) was also 
used as a substrate. This was stored at -20°C, 2.21 mg/ml H2O (4 mM). On the day of 
the experiment, the ATP was diluted, creating a concentration of 40 μM ATP. This was 
then diluted further to a 4 μM working solution. The ATP and GS2 were mixed in an 
Eppendorf to create a substrate solution of 50 μM GS2 and 2 μM ATP, making the final 
concentration in the well 25 μM of GS2 and 1μM ATP. 
All inhibitor compounds tested were diluted to 5 mM, by adding a volume of DMSO based 
on their molecular weight. When the assay began, these were further diluted in the 
reaction mixture to a final concentration of 50 μM. The Luminescent Kinase Assay 
(Sigma)(Kinase-Glo), used to produce the luminescence measured was stored at -20°C, 
and always kept protected from light. When the aliquots were prepared, the solid luciferin 
powder was kept in an amber glass bottle to protect it from light. 
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The controls used in this experiment were: 
 The ATP control: These wells had neither the enzyme nor an inhibitor, used to 
obtain the maximum fluorescence value, and therefore the minimum activity 
value for the enzyme.  
 The ENZ control: These wells contain the substrate mixture and the enzyme, 
but no inhibitor. This gives the value for 100% activity of the enzyme. 
Firstly, 10 μl of the inhibitor compounds (10 μM final concentration) were pipetted into 
each well, in duplicate. In the first 4 wells, the ATP and enzyme controls, DMSO was 
added as a vehicle control, with the same volume of kinase buffer. The enzyme and 
substrate solutions were then added to their respective wells. The plate was then placed 
in an incubator for 30 minutes at 30°C, for the reaction to take place. Once this incubation 
period was finished, the Kinase-Glo was added to each of the wells. The plate is then 
covered to protect the Kinase-Glo from light, and the reaction is left to progress for 10 
minutes. The plate is then placed into the Varioskan equipment (Thermofisher, USA), 
which measures the luminosity produced by the luciferin reacting. Once the Varioskan is 
finished with the plate, a set of luminosity data is produced and inserted into a 
spreadsheet. Following the subtraction of the average maximum positive values 
produced by the enzyme control, data were expressed as a percentage of the ATP blank. 
4.4.3 IC50 
The in vitro IC50 assays were all performed by a member of staff at the CSIC in Madrid 
using the standard luminosity IC50 methodology [61]. Three different concentrations were 
used to create the curve to derive the IC50 from. 
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4.5 Computational results 
4.5.1 Active/Decoy Ligand Set Results 
RMSD for Redocking Crystal Structure Ligands 
Root-mean-square-deviation (RMSD) is commonly used to validate the accuracy of 
docking protocols by re-docking the native pose of a ligand taken from a selected 
crystallographic complex back into the complex. RMSD for comparing two poses 
(predicted and experimental) is calculated using the equation below: 1 
𝑅𝑀𝑆𝐷 =  √
1
𝑁
∑ 𝛿𝑖
2𝑁
𝑖=1     Eq. 4.5 
where δ is the distance between the number of pairs (N) of equivalent atoms. The RMSD 
values were generated for each docking method and scoring function considered, by 
redocking the 2OW3 ligand back into its native site. As well as this, the poses of the other 
four actives present in the active/decoy ligand set that have solved crystal structures 
were also used in a cross-docking to the protein from 2OW3 to assess the similarity of 
their poses to that of their native crystal structures. The PDB codes for these ligands are: 
3I4B, 1UV5, 4ACG and 1Q3D.The structures of all 5 of these ligands are shown in Figure 
4.4, and the RMSD values for redocking are shown in Table 4.3. 
Figure 4.4: The structures of the 5 crystal complex ligands taken directly from their 
complex geometries in their bound conformations. A: 4ACG (CHEMBL2177173), B: 
3I4B, C: 2OW3 (CHEMBL1087499), D: 1Q3D (CHEMBL388978), E: 1UV5 
(CHEMBL3125370). Carbon atoms are displayed in green, oxygen in red, nitrogen in 
blue and sulphur in yellow. 
A B 
C 
D 
E 
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An RMSD of <2.0 Å is generally considered a good value for docking poses compared 
to their crystallographic conformations. For 2OW3 (C Figure 4.4), the values for Glide-
SP and Glide-XP, GOLD-ASP and GOLD-ChemPLP are all good RMSDs, less than 1Å. 
GOLD-ChemPLP, Glide-SP and Glide-XP are all Empirical Scoring functions, which 
could go some way to explain why their RMSD values are similar. The AutoDock scoring 
functions on the other hand, did not receive a score under 2 Å. The most plausible reason 
for this is the extremely large macrocyclic structure of the ligand, which may have caused 
the programs to penalize it based on its complexity. This could mean that these high 
RMSDs are not necessarily representative of what the RMSDs will be for all the other 
ligands in the database, which in general are a lot smaller.  
Table 4.3: Redocking RMSD (Å) results (native and cross) for all of the scoring functions 
tested, Glide-SP and -XP, AutoDock 4, AutoDock Vina, GOLD-ASP and GOLD-
ChemPLP. Scores below the generally accepted level of a good score (2.0 Å) are 
coloured green, scores just above this value are coloured amber, and scores more than 
3.0 Å above this value are coloured red. 
RMSD 
(Å) 
Glide AutoDock GOLD 
PDB 
Code 
SP XP 
AutoDock-
4 
Vina ASP ChemPLP 
2OW3 0.711 0.732 3.772 3.383 0.781 0.717 
3I4B 7.592 7.583 7.448 9.316 7.448 10.976 
1UV5 1.275 2.291 1.305 5.407 6.265 2.410 
4ACG 2.601 2.611 7.208 7.777 1.706 3.045 
1Q3D 1.275 0.925 5.518 5.277 3.010 1.752 
 
In contrast the ligand from PDB 3I4B (B Figure 4.4), another large ligand, received high 
RMSD values with all programs when cross-docked. While the crystal structure of 3I4B 
is positioned across the centre of the ATP binding site, the poses generated by the 
programs tended to bend around the cavity. This could be due to the shape of the 2OW3 
cavity being larger, or due to the fact that this molecule is highly flexible, allowing the 
programs to drastically alter its shape while scoring it. Another ligand, 1UV5 (E Figure 
4.4) received a very high RMSD of 5.407 Å with AutoDock Vina, which was much higher 
than the other programs, and a comparison between its pose and crystal structure can 
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be seen in Figure 4.5 below. The highest scoring pose has a high RMSD because it is 
flipped 180 degrees from the crystal structure pose. This, however, did not receive a 
docking score as bad as the RMSD would suggest. The reason for this could be that due 
to the shape of the molecule being similar on both sides, the score of the pose could 
have been improved greatly due to it being able to fit in the same space forming similar 
interactions. The cross-docking RMSDs are as expected not as good as those for the 
native redocking of the 2OW3 ligand. However, apart from the 3I4B ligand, RMSDs less 
than or close to 2 Å were obtained. 
 Figure 4.5: The crystal structure and the top AutoDock Vina pose for 1UV5 (Ligand E 
in Figure 4.4) superimposed on its crystal structure. The poses are flipped in relation to 
eachother, hence the RMSD of 5.407 Å. 
Statistical Analysis of Docking Performance 
The docking results produced by each of the programs used in the benchmarking 
screening (30 actives in a 2119 active/decoy set) were all assessed with Schrödinger’s 
Enrichment calculator, the results of which are shown in Table 4.5 below. Performance 
was measured in terms of the ability of the methods to correctly identify and rank actives 
high in the database screened. A number of statistical metrics were considered for this 
purpose. 
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Table 4.5: Statistical analysis of benchmarking (active/decoy) screening results for the 
different scoring functions. The best score for each statistical metric produced by the 
individual docking programs are shown in red italics, while the best scores in each row 
for the tested consensus methods are in blue italics. 
Statistical 
Parameters 
Glide  AutoDock  GOLD 
Consensus 
Method 1
a 
Consensus 
Method 2
b 
Consensus 
Method 3
c 
SP 
(GS) 
XP 
(GS) 
Vina  
Auto- 
Dock4 
ASP 
Chem
-PLP 
SS 
d ETW 
e SS 
d ETW 
e SS 
d ETW 
e 
AU-ROC 0.82 0.79 0.75 0.68 0.79 0.71 0.87 0.88 0.87 0.86 0.89 0.90 
BED-
ROC 
α=160.
9 
α=20.0 
α=8.0 
0.256 
0.382 
0.503 
0.177 
0.319 
0.457 
0.237 
0.299 
0.406 
0.109 
0.156 
0.263 
0.262 
0.408 
0.521 
0.115 
0.201 
0.334 
0.358 
0.465 
0.598 
0.318 
0.456 
0.600 
0.375 
0.434 
0.578 
0.326 
0.421 
0.565 
0.345 
0.455 
0.615 
0.328 
0.472 
0.630 
EF 
1% 20 13 13 6.7 20 6.7 24 17 24 20 24 17 
5% 7.3 7.3 6 2.7 8.7 4 11 9.3 8.7 8 8.7 10 
10% 5.3 4 4 2.3 5.3 2.3 6.7 6.3 6.3 6 7.3 7 
EF` 
1% 24 14 22 8 21 7.3 36 25 41 31 33 29 
5% 13 10 10 4.2 14 5.8 15 15 14 14 14 15 
10% 8.5 6.8 6.5 3.3 9.1 4 11 10 9.8 9.4 11 11 
a Glide XP and SP, GOLD ASP and ChemPLP, AutoDock Vina and AutoDock 4 b Glide-SP, Glide-
XP, GOLD-ChemPLP and AutoDock Vina. c Glide-SP and -XP, GOLD-ASP, and AutoDock Vina 
d Simple Sum rank consensus method e Deprecated Sum rank (Exclude the worst). Docking 
programs were chosen based on the scores of the consensus methods, not their individual 
scores, which were used for comparison with those of the consensus methods. 
In terms of individual programs and scoring functions, the two most accurate are shown 
to be Glide-SP and GOLD-ASP for the statistical parameters discussed in section 3.3.8. 
For AU-ROC, a value of 1 would indicate that a program returned all of the 30 actives as 
the top 30 ligands, where a value of 0.5 corresponds to random selection. The highest 
AU-ROC produced was Glide-SP with a value of 0.82, followed closely by GOLD-ASP 
(0.79) which was also equal to that of Glide XP. For the other methods, AutoDock Vina 
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(0.75), GOLD-ChemPLP (0.71) and AutoDock 4 (0.68), the values were all close to 0.7. 
To find the AU-ROC, a ROC plot is used. The ROC plots of Glide-SP, Glide-XP and 
GOLD-ASP, the three top performing programs in terms of AU-ROC are shown below in 
Figure 4.6.  
Figure 4.6: The ROC plots for the top 3 docking methods used and their AU-ROC values: 
(a) GOLD-ASP, (b) Glide-SP and (c) Glide-XP 
While the AU-ROC values show that these programs were able to return the actives quite 
early, they are not good enough alone to assess the usefulness of a docking program 
for virtual screening. The next statistical parameter, the Enrichment Factor (EF) 
(Equation 4.1) can be calculated for certain percentages of the total number of ligands 
tested. In Table 4.2, the top 1%, 5% and 10% of the database have all been analysed, 
however, due to the fact that in large screenings only the top most part of the results is 
investigated, the 1% value will be taken to have more importance in terms of the accuracy 
of the method. In the case of the benchmarking database, the top 1% contains 21 
compounds. For EF, a value of 1 would show that the programs ability to select actives 
from the database is equal to that of random selection. When the value is > 1, it multiplies 
the accuracy of the program at selecting an active from the database, for example a 
value of 4 would be four times better than random. Glide-SP and GOLD-ASP are the two 
highest scoring programs for EF, as they both received a value of 20 for the top 1%. This 
means that they are both 20 times better at returning actives in the top 1% compared to 
random selection. AutoDock Vina and Glide-XP are next, as they both produced a 1% 
(a) 
AU-
ROC = 
AU-
ROC = 
AU-
ROC = 
(b) (c) 
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value of 13. This is then followed by GOLD-ChemPLP and AutoDock 4, which both 
produced a value of 6.7. In Figure 4.7 the EF values of Glide-SP and –XP, GOLD-ASP 
and AutoDock Vina are shown for the different percentages (1%, 5% and 10%) where 
we can clearly see higher and better values at 1% (The improved performance via 
consensus scoring will be discussed later).  
Figure 4.7: A comparison of the EF values obtained by the various programs and 
consensus method 3 
Both AU-ROC and EF can be modified to account for the early recognition of compounds 
in the form of BEDROC (Equation 4.4) and EF’ (Equation 4.2). As discussed above, in 
section 4.3.8, EF’ is a version of EF that has been modified to take into account the early 
return of actives. BEDROC also focuses on early retrieval. The three BEDROC α values 
are similar to the three EF’ percentages (1%, 5% and 10%). Similar to EF, we will focus 
on the 1% for EF’ and the α value of 160.9 for BEDROC. The highest EF’ value produced 
by any of the programs was a value of 24 for Glide-SP. Its BEDROC value was 0.256. 
GOLD-ASP on the other hand, which had the same value for EF, only received an EF’ 
value of 21. While GOLD-ASP produced a BEDROC value similar to that of Glide-SP 
(0.262) its lower EF’ value would indicate that Glide-SP was more accurate overall at 
selecting actives in the top 1%. While Glide-SP and GOLD-ASP returned the same 
number of actives in that section (1%), Glide-SP returned them earlier than GOLD-ASP. 
This means that EF’ and BEDROC can be used to further differentiate between programs 
that produced the same EF values. Another example of this is AutoDock Vina and Glide-
XP, which both produced the same EF value of 13. However, the 1% EF’ value for 
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AutoDock Vina was 22, with a BEDROC value of 0.237, whereas Glide-XP produced 
lower values for both, with an EF’ of 14, and a BEDROC of 0.177. AutoDock 4 and 
GOLD-ChemPLP had the lowest and similar EF’ values of 8 and 7.3, respectively. The 
BEDROC were likewise similar at 0.109 and 0.115, respectively. Figure 4.8 below shows 
comparisons of the values for EF’ and BEDROC of different docking programs. Again, 
the discussion of consensus method three can be found below. 
Figure 4.8: A comparison of the EF’(above) and BEDROC(below) values for each of the 
docking programs with those of the consensus method 3 
Along with the statistical analysis, another good indicator of the comparative accuracy of 
each of the programs is to look at the ranks received by each of the 30 active compounds, 
shown below in Table 4.6. As can be seen, the native ligand for 2OW3, 
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CHEMBL1087499 (bis-(indole)malemide pyridinophane shown in Figure 4.2), was 
returned at an early rank by all six of the calculations. While this was an expected result, 
due to it being the native ligand, the fact that all of the programs recognised this ligand 
as a strong active is a good sign. The ligand was ranked first by both AutoDock programs, 
a stark contrast to the higher RMSD values these programs produced with the crystal 
structure, and the lowest rank it received was 28 (GOLD-ChemPLP), which was the only 
rank that placed it outside the top 1%. Actives that were ranked highly, were generally 
done so by a number of methods. Overall, most actives were ranked well by at least two 
programs. 
Table 4.6: The ranks for the 30 known active compounds received from each of the 
docking programs used. The native ligand (2OW3) is shown in red. 
Active Vina AutoDock Glide-XP Glide-
SP 
ASP CHEMPLP 
3I4B 758 296 240 206 595 217 
CHEMBL1086735 573 1014 66 40 917 1741 
CHEMBL1087499/2OW3 1 1 10 4 18 28 
CHEMBL1092754 224 1033 383 48 50 268 
CHEMBL1099297 865 1650 481 1266 285 355 
CHEMBL1684800 33 858 1535 255 156 2 
CHEMBL1940907 1576 1850 75 49 429 730 
CHEMBL2048675 267 416 214 138 20 325 
CHEMBL2071201 1494 849 816 823 515 938 
CHEMBL215803 25 92 2085 790 1222 1640 
CHEMBL2177173/4ACG 268 1719 486 170 14 122 
CHEMBL2386093 2 17 25 11 38 452 
CHEMBL2443026 34 543 1196 715 544 328 
CHEMBL255735 1085 471 103 145 642 1024 
CHEMBL270473 47 326 5 3 6 31 
CHEMBL3085387 672 479 377 358 1577 1420 
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CHEMBL3091543 759 696 373 148 458 454 
CHEMBL311228 1890 1856 1198 949 252 838 
CHEMBL3125370/1UV5 574 74 42 20 1983 1729 
CHEMBL317657 225 463 16 18 762 559 
CHEMBL361708 1577 503 97 33 1933 2097 
CHEMBL362155 5 195 763 709 7 64 
CHEMBL380946 183 402 18 17 512 252 
CHEMBL388978/1Q3D 48 626 30 60 89 288 
CHEMBL402902 673 595 338 679 455 848 
CHEMBL403405 269 681 914 311 59 411 
CHEMBL412142 1086 1925 255 1053 129 595 
CHEMBL472043 575 458 175 1137 30 79 
CHEMBL562089 270 1444 833 405 3 20 
CHEMBL65987 576 1203 333 904 9 387 
 
Consensus Scoring Method 
Various combinations of the docking programs in terms of consensus scoring methods 
were tested, to see which method was the most accurate at recognising the actives in 
the benchmarking library. This was done by applying either a simple sum rank (section 
4.3.7) or depreciated sum rank (Exclude the worst), to the various combinations of 
programs. The statistics of the three main combinations are shown in Table 4.5, where 
they can be compared with the performances of the individual programs. As can be seen 
from Table 4.5, deprecated sum rank consensus scoring performed consistently worse 
than simple sum ranking and therefore will not be discussed further. 
The first consensus method (Consensus Method 1) that was analysed with the 
benchmarking database was the combination as follows: Glide-SP, Glide-XP, AutoDock 
4, AutoDock Vina, GOLD-ASP and GOLD-ChemPLP. The statistics produced by 
consensus scoring are shown in Table 4.5. Each statistical metric produced values 
superior to those of the individual programs e.g. EF’(1%) was 36 compared to the best 
value of 24 for an individual program (Glide-SP). However, during the full virtual 
screening, problems arose with the use of AutoDock 4, the program constantly struggled 
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with the size of the screening library. As well as taking over a month to finish the 
screening the program crashed constantly. It was therefore decided that a method would 
be designed that did not use AutoDock 4, as these problems were preventing the project 
from continuing. 
Once AutoDock 4 had been removed from the various different combinations, there were 
two that gave similarly good results in terms of the statistics. Consensus Method 2 
contained: Glide-SP, Glide-XP, AutoDock Vina and GOLD-ChemPLP and Consensus 
Method 3 contained: Glide-SP, Glide-XP, AutoDock Vina and GOLD-ASP 
Both Consensus Method 2 and Consensus Method 3 contain 3 different search 
algorithms and 4 different scoring functions. They both outperformed the individual 
docking programs in all of the statistical metrics, for example their EF (1%) values of 24, 
compared to the highest single program which is Glide-SP with 20 as can be seen from 
Table 4.5. While their EF values are the same, Consensus Method 2 received the best 
1% EF’ (41) compared to that of Consensus Method 3 (33). For the actual screening, 
157,238 ZINC compounds, both methods 2 and 3 were initially applied. 
However, it was found that due to simple sum ranks being a total of their ranks across 
all of the programs, the totals for each ligand for method 2 were much higher than those 
of combination 3. Therefore method 3 produced a much closer consensus of the potential 
activity of the compounds in the screening library than method 2. As the aim of this 
screening is to use a selection of programs to obtain a largely unanimous consensus, 
this was deemed more beneficial to the results than having slightly better statistics in the 
benchmarking calculation. For example, despite method 3 having a lower value for the 
1% of EF’, this value only represents one or two actives performing better in the 
benchmarking database. On this basis Consensus Method 3 was applied, and the virtual 
screening was completed, taking around 4 to 5 weeks, with Glide-SP finishing the fastest. 
Pharmacophore based analysis of virtual screening results 
Once the virtual screening of the filtered database and ranking using Consensus Method 
3 was completed, aided by the KNIME workflow shown in Figure 4.3, we selected the 
top ranked 200 compounds for further consideration. Another possible method that could 
help identify hits in our top 200 compounds was the design of a series of pharmacophore 
models that could identify compounds with groups conducive for favourable binding. The 
original attempt to design a pharmacophore model was based on all of the 30 active 
compounds in our active/decoy training set. However, the pharmacophore models 
produced were inaccurate in distinguishing the 30 actives from the 189 inactives, 
possibly due to the diversity within the active set; additionally confgen was used to 
generate the conformations. So, instead it was decided that a selection of X-ray 
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crystallographic poses of known active inhibitor compounds from a paper by Doerksen 
et al [72] would be used. 17 active inhibitor PDBs were selected from the paper, and the 
ligands were used in the poses in the PDBs, after the complexes had all been 
superimposed (PDBS: 2OW3, 1Q3D, 1Q3W, 1Q4L, 3I4B, 1UV5, 4ACG, 1Q5K, 1Q41, 
2O5K, 3DU8, 3F7Z, 3F88, 3Q3B, 4ACC, 4ACD and 4ACH). Once the models had been 
designed, three were chosen, one 3-point, one 4-point and one 5-point pharmacophore. 
Table 4.7 below shows the statistics created for these and all pharmacophores (c.f. 
Section 4.3.9) by Phase [111] for all the Pharmacophores that were developed. 
Table 4.7: The statistics for each of the pharmacophores generated by Phase [v4.5]. 
The models shown in bold were the three final models chosen (3-point, 4-point and 5-
point pharmacophores) 
No of Sites: Hypothesis a Survival 
score 
Survival 
inactives 
Active-
Inactive 
#MATCHES b 
3 ADR.6 6.269 5.303 0.966 15 
3 ADR.16 6.220 5.325 0.895 15 
3 ADR.8 6.171 5.275 0.896 15 
4 AADR.42 3.438 2.631 0.807 5 
4 AARR.29 3.412 2.524 0.888 5 
4 ADRR.11 2.836 1.743 1.093 9 
5 AAADR.3 3.024 2.078 0.946 5 
5 AAADR.2 2.742 1.724 1.018 5 
5 AAADR.1 2.531 1.544 0.987 5 
a A = H bond acceptor, D = H bond donor, R = Aromatic group b The number of actives out of the 17 
inhibitors that matched the pharmacophore 
The pharmacophores that were chosen were ADR.6 (3-point), ADRR.11 (4-point) and 
AAADR.3 (5-point) where A = H-bond acceptor, D= H-bond donor, R= Aromatic group. 
These were chosen based on mainly the Survival scores of the actives compared to 
those of the inactives (Active-Inactive)(Table 4.11) and represents the active survival 
score minus the inactive survival score. The higher the value, the greater the selectivity 
for actives over inactives. Another factor used in the design of these models was how 
many of the actual actives used in the design of the models fit the models: 15 for the 3-
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point, 9 for the 4-point and 5 for the 5-point model. The 3D models of each of the three 
pharmacophores chosen are shown in Figure 4.9 below.  
Figure 4.9: The 3D models of the three pharmacophores that were designed for use in 
this project. (a) ADR.6 the 3 point pharmacophore, (b) ADRR.11 is the 4 point 
pharmacophore and (c) AAADR.3 the 5 point pharmacophore. The red spheres indicate 
hydrogen bond     acceptors, the blue spheres indicate hydrogen bond donors, and the 
orange rings indicate aromatic groups. 
These pharmacophores were then applied to our top 200 compounds. The number of 
compounds that fit the 3 point pharmacophore is 138, the 4 point pharmacophore fit 64 
compounds, and the 5 point model fit 9. Data regarding which of the compounds fit the 
pharmacophore models produced after the virtual screening was added to the consensus 
method results using KNIME to be used as additional information for selecting the final 
compounds. These pharmacophore models were used at this stage after the virtual 
screening so that it did not reduce the number of compounds screened and particularly, 
the diversity. The full set of results (selection criteria) for the top 200 compounds are 
shown in the Appendix (Table S.1) 
(a) (b)
(c)
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4.5.2 Selection of the compounds for purchasing 
A total of 10 compounds (Figure 4.10) were selected for purchasing for the type I 
biological studies. Of these compounds, 6 were purchased from Enamine Ltd 
(ZINC000159432235, ZINC000273149682, ZINC000294625147, ZINC000355536096, 
ZINC000268128830 and ZINC000189195311) with purities of >95% in amounts of 3mg. 
The other 4 (ZINC000067820131, ZINC000072152229, ZINC000096131333 and 
ZINC000028406051) were purchased from Molport, with purities of above 90% in 
amounts of 1mg to 3mg. These compounds were selected by taking into account their 
consensus scoring rank, various ranks from the individual programs, as well as their 
binding interactions, and how well they fit the three pharmacophore models (Table 4.8). 
Another factor in the decision to select these compounds for further study was the 
diversity of their binding modes. While the hinge region has great importance in the 
binding of inhibitors to the ATP binding site, it has already been explored in great detail 
[30], and to avoid trying to “reinvent the wheel”, we allowed for a much higher diversity 
in the selected compounds. On top of this, Bharatam et al. [90] outlined a selection of 
interactions that ligands can have with the enzyme that improved kinase selectivity. Key 
examples of this are residues Phe67, Arg141, Pro136 and Cys199. These interactions 
were also searched for with our selected ligands.  
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Figure 4.10: The structures of the 10 potential type I inhibitors selected for further testing 
from the completed in-silico study. They are in order: (1) Z189195311, (2) Z27314982, 
(3) Z355536096, all three of which are all Pyrazole derivatives, (4) Z28406051, a 
derivative of Pyrazolo Pyrimadine, (5) Z67820131, a Pyrimidinone, (6) Z72152229, an 
Imidazole, (7) Z96131333, a Triazole, (8) Z159432235, a Napthyridine, (9) Z294625147, 
a Pyperazine, and (10) Z268128830 an Indazole. 
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Table 4.8: The consensus ranks from method 3, individual program ranks and other 
information used to select the 10 compounds chosen for biological assessment. 
 
As can be seen from Table 4.8, the compounds that were selected range in consensus 
rank between 6 and 152. Similar to the actives in the benchmarking study, all of these 
compounds were ranked well (possible ranks 1-157,238) by the individual programs 
used in the consensus method. Very few compounds received more than one rank over 
5000 and generally at least 2 docking programs ranked each compound in the top 1% 
(<1572). The table also shows that the compounds selected have at most 4 rotatable 
bonds, with the average being 2.4. This shows that they are relatively rigid, an important 
quality for inhibitors and also values were consistent with blood brain barrier activity. The 
range of molecular weights for the 10 compounds is 280-396 Da which, when compared 
to bis-(indole)malemide pyridinophane ligand native to 2OW3 (541.665 Da) is much 
smaller but similar to that of other active ligands. On top of this, they all received a CNS 
value of 1, which indicates the ability to cross the blood brain barrier, further validation 
of this would involve an in vitro blood brain barrier model. The final set of information 
shown in Table 4.12 is the ability of each compound to match the 3 developed 
pharmacophore models. While all but one of the chosen compounds fit the 3-point model, 
only 4 fit the 4-point pharmacophore. The 5-point pharmacophore produced no matches 
with any of these compounds, however, this is unsurprising, as we selected molecules 
of a smaller size, meaning that the 5-point pharmacophore tended to be too large. It was 
Title Consensus 
Rank 
SP 
Rank 
XP 
Rank 
ASP 
Rank 
Vina 
Rank 
#rotor CNS Mw 
(Da) 
3Pt 4Pt 5Pt 
Z67820131 6 287 463 1714 252 3 1 379.504 1 1 0 
Z355536096 7 1050 649 142 990 4 1 347.419 1 1 0 
Z159432235 20 68 50 282 5542 3 1 364.403 0 0 0 
Z72152229 24 94 1557 926 3992 1 1 310.401 1 0 0 
Z96131333 50 5033 1777 1098 1172 0 1 341.455 1 0 0 
Z273149682 89 4308 3641 2281 1757 4 1 357.411 1 0 0 
Z28406051 92 80 173 7889 3918 2 1 327.816 1 1 0 
Z189195311 98 758 2601 7866 1692 2 1 395.547 1 0 0 
Z268128830 125 722 7717 4785 1258 2 1 281.316 1 0 0 
Z294625147 152 5 640 5131 10314 3 1 292.285 1 1 0 
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also found that the 5-point pharmacophore matched compounds that were highly flexible 
in the top 200 (Table S.1), due to its large size, and therefore the ability to fit the 5 point 
model was not weighted as much as the 3 and 4-point models. 
4.6 Biological results 
4.6.1 Type I Luminosity assay results 
The 10 compounds chosen for in vitro studies are shown in Figure 4.10. The first assay, 
involves the use of the GSK-3β enzyme to phosphorylate the substrate GS2 using ATP, 
which is then converted to ADP. There is also a second reaction employed after the first 
in this assay. This reaction uses ATP to convert beetle luciferin to Oxyluciferin +(Figure 
4.12), which produces luminescence. 
 
Figure 4.12: The structures of luciferin (left) and oxyluciferin (right) 
Due to the fact that both consume ATP as part of the reaction, the second luminescence 
reaction can be used to quantify the activity of the enzyme during the first. This is 
because the stronger the luminescence produced, the more ATP is left over from the 
enzymatic process. Therefore if compounds that are able to inhibit the activity of GSK-
3β are included in the first reaction then there will be more ATP available for the second, 
linking luminosity to % inhibition quantitatively. The results of this assay are recorded as 
a percentage of inhibition relative to the 100% ATP (average negative) and 0% enzyme 
(average positive) controls. This is calculated using the equation: 
%𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = 100.0 ×
(𝑅𝑎𝑤 𝑑𝑎𝑡𝑎 𝑜𝑓 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑−𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒)
(𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒−𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒)
    Eq. 4.5 
No changes to the method were made during the assay, and the results that were 
obtained are shown below in Table 4.9. 
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Table 4.9: the experimental data produced for each of the 10 Type I compounds that 
were tested in the assay. The only compounds that produced an inhibition of over 50% 
(relative to the ATP control) at 50 mM is shown in bold. 
Type 1 
Compounds 
Compound number 
(Zinc code) 
Mw Purity 
(%) 
% 
Inhibition  
IC50 
(μM) 
71574548 Compound 5 
(ZINC000067820131) 
379.508 >90 21.04±2.
55 
- 
43020696 Compound 6 
(ZINC000072152229) 
310.405 >90 74.58±1.
49 
24.69
±0.73 
13803800 Compound 7 
(ZINC000096131333) 
341.459 >90 20.11±2.
17 
- 
STK889681 Compound 4 
(ZINC000028406051) 
327.82 >90 22.64±3.
08 
- 
Z1505361204 Compound 8 
(ZINC000159432235) 
364.405 >95 1.61±3.8
1 
- 
Z1654883190 Compound 2 
(ZINC000273149682) 
357.414 >95 1.05±2.2
6 
- 
Z2226503926 Compound 9 
(ZINC000294625147) 
292.285 >95 4.33±1.6
0 
- 
Z3183855702 Compound 3 
(ZINC000355536096) 
347.422 >95 25.19±1.
57 
- 
Z1408593245 Compound 10 
(ZINC000268128830) 
281.319 >95 1.22±1.2
2 
- 
Z1764937623 Compound 1 
(ZINC000189195311) 
395.551 >95 20.92±2.
03 
- 
 
As can be seen from the table, we obtained a range of percentage inhibitions, with the 
highest being ZINC000072152229 (Compound 6, Figure 4.10) with 74.58% and the 
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lowest being ZINC000273149682 (Compound 2) with 1.05%. 6 compounds in total 
received an inhibition of over 20% and only one received an inhibition of over 50%. A 
noticeable trend in the results however, is that the compounds that were supplied by 
Enamine Ltd. mostly struggled to achieve an inhibition of over 5%. On the other hand, 
every compound that was ordered form Molport produced an inhibition of over 20%. The 
binding modes of the two compounds with the highest percentage inhibitions, Compound 
6 and Compound 3 are shown in Figure 4.13. 
As can be seen in Figure 4.13, both of the two best performing ligands formed multiple 
interactions with the hinge region (hydrogen bonding with Asp133 O and Val135 NH). 
This is unsurprising, as hinge region interactions greatly increase the potency of kinase 
inhibitors. The best performing ligand, Compound 6 (ZINC000072152229), as well as 
forming two interactions with the hinge region, hydrogen bonds with the Asn96  sidechain 
O towards the back of the site. These interactions keep the ligand, locked in its position. 
The positively charged nitrogen of the ligand is positioned near the acid group of Asp200, 
allowing a strong ionic interaction to take place (seen clearly in the 2D representation). 
In terms of selectivity, compound 6 only formed one of the interactions Bharatam et al. 
described as favourable, a π-cation bond between the positive nitrogen and the phenyl 
ring sidechain of Phe67. Compound 3 (ZINC000355536096) on the other hand forms 3 
hydrogen bond interactions, all with the hinge region. The only other interaction it forms 
is the selective π- π stacking interaction with Phe 67. Its IC50 value 24.69±0.73 μM  
The similarity in interactions between these two ligands cause them to have comparable 
binding modes. Neither ligand forms any strong selective interactions and the bulk of 
their binding happens at the hinge region. The biggest difference between the binding 
modes of these two compounds is the strong ionic interaction between compound 6 and 
the acid of Asp200. This interaction is therefore likely the cause of the large difference in 
potency. However, compound 3 was chiral, purchased as a racemic mixture, so here in 
relativity the R enantiomer that we screened is likely to have a greater inhibition value, 
as the other enantiomer in the racemic mixture has no potency. 
 70 
 
Figure 4.13: The binding modes, in 2D and 3D, of the two inhibitor compounds with the 
highest percentage inhibition values, A) Compound 6 (ZINC000072152229) (74.58%) 
and B) Compounds 3 (ZINC000355536096) (25.19%). 
 
 
 
 
A) 
B) 
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4.6.2 Type I IC50 Assay Results 
As it was the only compound of the 10 tested to receive an inhibition of over 50% at 
50μM, ZINC000273149682 (compound 6) was the only compound to have its in vitro 
IC50 tested. The plotted graph of this is shown below, in Figure 4.14, and the IC50 taken 
from this graph is 24.69 ± 0.73 μM. 
Figure 4.14: The % activity of GSK-3β plotted against concentration of the inhibitor 
ZINC000273149682. 
While this value is relatively high when compared to the IC50 of the native ligand of 2OW3 
(3 nM), it shows the ligand has potential for modification to improve its binding affinity. 
The lower potency of compound 6 will also cause it to have reduced toxicity, as well as 
a reduction in the potential for side effects.  
4.7 Conclusion 
From the results of the benchmarking screening shown in this chapter it can be 
concluded that the consensus scoring was successful in terms of more accurately 
selecting active compounds from an active/decoy training set of ligands. The first 
evidence of this is the statistical values produced for EF (Figure 4.7), EF’ and BEDROC 
(Figure 4.8) by the final consensus method. The values for each of the metrics are all 
significantly greater than those of the individual programs. This shows that the 
consensus method consistently outperformed the individual programs in the 
benchmarking study. On top of the consensus scoring method that was used, other 
methods of improving the accuracy of the results were also trialled. The pharmacophore 
models served to create an extra set of data with which the accuracy could be improved. 
As can be seen from the final 10 structures of the compounds selected, while they are 
diverse, they also share common features. We tried to select compounds with various 
other interactions as well as inhibitors that bind to the hinge region, which have been 
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explored in depth as we wanted to avoid “reinventing the wheel”. The results of the 
luminosity assay showed 6 of our 10 compounds to have a percentage inhibition of over 
20%, with compound 6 even receiving a value as high as ~75% at 50 μM , and an IC50 
of 24.69 ± 0.73 μM. As compound 6 binds mainly via the hinge region, its activity was 
not a large surprise; however, it also forms an ionic interaction at the back of the binding 
site with Asp200. The ligand is not inherently selective, however, further modifications 
could be made to improve its selectivity at a later stage. Looking at these results, the 
best course of action is possibly picking ligands with a larger amount of hinge 
interactions, and to take more into account the ligands size and flexibility, as the better 
performing ligands were smaller and more rigid. Based on the data obtained in this 
project, and looking at the compounds that were successful and those that were not, 
these two are factors affecting potency. Ionic interactions similar to that of compound 6 
should also be searched for, as this interaction caused a clear increase in activity 
compared to the similarly binding compound 3. 
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Chapter 5: In Silico Screening and Experimental Validation of GSK-3β Type II 
Inhibitors 
5.1 Introduction 
Alzheimer’s disease (AD) is a neurodegenerative disease, and the most common type 
of dementia present in the world today. As all the treatments that are currently available 
do little more than alleviate the symptoms of the disease, there is a real need for new 
effective treatments to be designed, as the number of patients rises. Hooper et al. [18] 
published ‘The GSK-3 Hypothesis of Alzheimer’s Disease’ in 2007, a paper summarising 
the evidence of the involvement of a Ser/Thr kinase; Glycogen Synthase Kinase-3 beta 
(GSK-3β), in the formation of amyloid plaques and neurofibrillary tangles. Therefore, 
inhibition of the enzyme has the potential to block the formation pathways of these two 
pathological features, producing a sorely needed new treatment for AD. While the type I 
inhibition (ATP binding site) of this kinase has been well explored, it suffers from large 
selectivity issues, and as such, researchers are turning to other types of inhibition. Type 
II inhibition in kinases is much less common than type I, and has the potential to be much 
more selective [112]. It involves the binding of inhibitors to the DFG-out conformation of 
the binding site (Figure 5.1), in which the DFG activation loop flips, placing the sidechain 
of the phenylalanine outside of the loop. This causes the opening of a new allosteric 
pocket that can be occupied by an inhibitor, preventing the loop from returning to its 
original position. 
Figure 5.1: The difference between the DFG-in (left) and DFG-out (right) conformations 
of the activation loop in ABL kinase, co-crystallised with imatinib. The respective PDBs 
are 2GOG and 1IEP. 
The opening of this loop also positions the backbone of the aspartic acid of the DFG-in 
such a way that allows formation of the “classical” interactions of a type II inhibitor, (a) 
one hydrogen bond with the DFG loop Asp, (b) one or two with the Glu from the αC helix 
and (c) an interaction with the hinge region. Type II inhibition is a much newer field than 
type I, and as such has not been fully proven to work with GSK-3β, as it is not possible 
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with all kinases. There are a number of factors that could prevent type II inhibition, the 
key factors being intermolecular interactions preventing the DFG loop flip, as well as the 
gatekeeper residue, which occupies the space near the opening of the allosteric pocket. 
If this gatekeeper is too large it can block the binding of inhibitors even if the loop is 
flipped out. Recently, Grütter et al [56] published evidence of the Ustilago Maydis form of 
GSK-3β undergoing type II inhibition. While doing this they also showed the same type 
II inhibitors interacting and inhibiting (although less strong) the human form of the 
enzyme, potentially indicating that the type II inhibition of human GSK-3β is possible. If 
true, this would provide a selective new option of the inhibition of the enzyme as a 
possible pathway towards ne AD treatments. In this chapter, we present the in silico 
design of two different DFG-out models, created using two different methods. The first 
will be created using DOLPHIN (Deletion Of Loop PHe-gly-IN) docking, which is a 
method of creating a Type II screenable structure without forming a DFG-out 
conformation. Proposed in a paper by Kufareva et al [34], DOLPHIN involves the deletion 
of the phenylalanine from the DFG loop, along with the next 4 residues. The deletion of 
this section does not affect any of the important interactions that are formed in Type II 
complexes in this area of the site, for example the hydrogen bonds with the glutamine of 
the C-Helix, and the hydrogen bond with the aspartate of the DFG loop. The conservation 
of these interactions means that even though a section of the loop has been deleted, the 
binding mode of type II inhibitors can still be accurately explored. The second will be 
made using a combination of Prime loop prediction to flip the DFG loop out, induced fit 
docking to further refine the site around a known type II inhibitor (sorafenib) and then 
molecular dynamics for a final structural refinement. These models were then used to 
screen a database of compounds taken from the Biogenics subset of the ZINC database 
[33]. The results of these screenings were combined into a consensus score, and this was 
used to select 20 potential type II inhibitors. Following this, these compounds were taken 
to the Consejo Superior De Investigaciones Cientificas (CSIC), for in vitro validation 
binding assays of enzyme inhibition. 
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5.2 Aim 
To design two accurate DFG-out models of GSK-3β for use in the in silico screening of 
a database for the selection of a group of potential type II inhibitors. The in vitro testing 
of the selected candidates with human GSK-3β will then follow this. 
5.2.1 Specific Objectives 
 To design two DFG-out models of GSK-3β, using two different techniques; 
DOLPHIN docking and Prime/Molecular Dynamics predictions 
 To validate these models using known inhibition data of sorafenib and BIRB 
analogues from Grütter’s paper 
 To use these two designed models for GSK-3β type II inhibition to screen a 
subset of the ZINC database for potential lead compounds 
 To choose a selection of compounds from the in silico screening for biological 
validation, with the human GSK-3β 
 
5.3 Computational Methods 
5.3.1 Creation of the Type II Validation Ligand Set 
A set of ligands were first used for validating the designed type II models. For this, 8 
ligands of the two type II inhibitor scaffolds, sorafenib (3 analogues) and BIRB (5 
analogues) previously studied for human GSK-3β inhibition (as well as fungal Ustilago 
Maydis GSK-3β inhibition) were chosen. Their structures, together with their inhibition 
data is shown below in Figure 5.2. These ligands were built using Maestro and prepared 
for docking using LigPrep, at a pH of 6-8 with the chiralities determined from the 3D 
structure. After Ligprep [v3.6] the total amount of ligands was still 8, and this ligand set 
was ready for the validation screenings.  
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Figure 5.2: The analogues of sorafenib and BIRB used to create the validation ligand 
set together with their inhibition data against human GSK-3β. IC50 against fungal Ustilago 
Maydis GSK-3β are given in parenthesis. (a) sorafenib, (b) sorafenib 16, (c) sorafenib 
17, (d) BIRB, (e) BIRB 12, (f) BIRB 13, (g) BIRB 14 and (h) BIRB 15 
5.3.2 Acquisition of the Biogenics Subset Database from ZINC15 
The Biogenics subset from the ZINC15 database was used for the actual virtual 
screening. The Biogenics subset is a database containing 135,000 compounds, 61,000 
of those being purchasable. The purchasable filter was applied to the Biogenics subset 
and the compounds were downloaded. When the purchasable compounds were 
downloaded, only 47,000 natural products and their derivatives and chemically modified 
versions were openable in Maestro. Once the subset was fully downloaded, the 
structures were minimised with Macromodel, using OPLS3 as the force field, TCNG 
(Truncated Newton Conjugate Gradient) was selected as the minimisation method, and 
the maximum iterations used was 300. The rest of the settings were left as their defaults. 
8.3±0.8 μM (0.71±0.2 μM) 
0.86 ±0.2 μM (1.4 μM) 
3.3±0.6 μM (1.9 μM) 37 μM (1.0 μM) 
>50 μM (1.8 μM) >50 μM (1.4 μM) 
>50 μM (6.9 μM) >50 μM (4.0 μM) 
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Qikprop [v4.6] was then used to predict values with which to filter the compounds, all 
settings for this were left as default. It was filtered using the filter rules shown in section 
4.3.2 (MW ≥ 200 and ≤ 650, logP O/W between and including 0 and 5, amount of 
Hydrogen Bond Acceptors (HBAs) on the molecule ≥ 0 and ≤ 10, amount of Hydrogen 
Bond Donors (HBDs) on the molecule ≥ 0 and ≤ 5, number of rotatable bonds less than 
or equal to 8 and a predicted CNS of 0 or above) to increase the potential of the 
compounds to cross the blood brain barrier, which left 27286 compounds. This filtered 
screening database was prepared using the same LigPrep protocol as the validation 
ligand set. Once the database was prepared, the total ligand amount came to 45092 with 
tautomers and ionisation states. 
5.3.3 DOLPHIN Model 
Model Creation 
The PDB that was used to create this DOLPHIN model was 2OW3. The preparation of 
the protein was carried out with Schrödinger`s Protein Preparation Wizard[113]. Water 
molecules more than 5 Å from heterogenic groups were removed, bond orders were 
assigned and all missing hydrogen atoms were added. The OPLS3 forcefield was used 
for a restrained minimisation to refine the system, with heavy atom convergence set to 
an RMSD of 0.3 Å to remove steric cla 
shes. The rest of the water molecules were then removed to prepare the enzyme for a 
subsequent docking. Using Schrodinger’s Maestro, the phenylalanine of the DFG loop 
(Phe201) was selected and deleted, along with the next 4 residues (202-205). A Glide 
grid-generation was then attempted, however, it failed due to incomplete valences. In 
the original DOLPHIN paper they had left these sections uncapped, however, as this was 
not possible in Maestro, the use of a hydrogen atom to cap the backbone sections that 
had incomplete valences was investigated. Upon contact with the author, the possibility 
of using these caps was discussed, it was decided that it would not affect the overall 
accuracy of the models structure. Once these sections had been capped, the Glide grid 
generation was then continued. Furthermore, the use of a similar approach in the original 
paper yielded consistent results with the electrostatic/DOLPHIN approach.  
DOLPHIN Docking Details 
To create an initial Glide grid for positioning a ligand into the site, the centre of a selection 
of residues was chosen to be the centre of the grid (dimensions; x = 30 Å y = 30 Å z = 
30 Å). These residues were: the hinge region (Asp133-Val135) and the DFG loop 
Asp200. Then to obtain a second and more accurate grid for the validation of the model 
and the subsequent screening, sorafenib was docked to the newly created site with 
Glide-SP, the most accurate individual docking program from the type I study (Table 4.5). 
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In terms of settings, OPLS3 was used as the forcefield, the van der Waals radii factor 
was set to 0.80 and the partial charge cut off was set to 0.15. Flexible ligand sampling, 
nitrogen inversion sampling and the sampling of ring conformations including input ring 
conformations were selected also. For results output after the calculation, post docking 
minimization was selected, along with strain correction terms. Once this docking had 
been completed, one of the poses for sorafenib that clearly showed a type II style binding 
mode was selected as the centre of the second Grid, that would be used in all future 
screenings and dockings with this DOLPHIN structure (dimensions; x = 29.513 Å y = 
29.513 Å z = 29.513 Å). Essentially, using this new grid, the analogies of sorafenib and 
BIRB (Figure 5.2) were screened to validate the model. Once the model had been 
validated, the same settings as the previous docking were used in a virtual screening 
with the full Biogenics subset database. 
5.3.4 Prime/Molecular Dynamics Model 
Loop Refinement 
The second method that was used to design a type II structure of GSK-3β for the virtual 
screening Prime [114] loop prediction. The protein prepared in section 5.3.2 prior to the 
deletion of the 5 residues was used for the calculations. Prime uses a selection of 
rotomer libraries, as well as the OPLS3 force-field [110] to explore new conformations of a 
selected loop of a protein. It was therefore decided that this sampling technique could 
potentially be used to produce a DFG-out structure, for us to refine further. To initially 
test this method, we first ran a loop prediction on the Ustilago Maydis form of GSK-3β 
(prepared using the same method as section 5.3.2 with no residues deleted) that was 
shown to undergo Type II inhibition in Grütter’s paper. Therefore, because it is known to 
form a DFG-out experimentally, Prime should also be able to do so. 
In terms of settings, the solvation model used was VSGB; the forcefield used was OPLS3 
and the loop selected for refinement was residues 199-204. Pleasingly, the loop 
prediction did produce a DFG-out conformation, with an energy of -13441.3 kcal/mol, 
which was ranked 27 (shown below in Figure 5.3) compared to the top ranked DFG-in 
conformation (-13445.8 kcal/mol). 
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Figure 5.3: The DFG-in conformation (a) of Ustilago Maydis GSK-3β obtained using 
Prime loop prediction, compared to the DFG-out (b)  
 Based on this, we used the same settings for simulating the human form DFG-out loop 
conformations. However, this did not produce a DFG-out conformation. When 
investigated further, in Grütter’s paper, it suggests that the salt bridge residues of 
Lys103, Gln206 and Phe175 could be the cause of this (Figure 5.4), as it is not present 
in the fungal form. The Prime loop prediction was tried again, but this time the Lys103 
residue was mutated to an isoleucine (Ile), which is the same as the residue from the 
fungal form, and this produced the DFG-out conformation as described in the results 
section. The mutated residues (not part of the DFG loop) were restored based on their 
positions in the original structure (via superposition). A further prime refinement was then 
performed using the same settings as before. 
 
 
 
a) b) 
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Figure 5.4: The salt bridge between residues Lys103, Gln206 and Phe175 that 
prevented the initial formation of the DFG-out conformation. 
Induced Fit Docking 
The next step was to use IFD to further refine the new DFG-out conformation from the 
loop prediction around a type II inhibitor pose. The ligand pose used for the centre of the 
grid was the sorafenib pose from the final DOLPHIN grid, superimposed into the site. As 
for the IFD settings, the forcefield used was OPLS3, and the standard protocol that 
generates up to 20 poses was applied, and residues within 7 Å of the ligand set as 
flexible. Two residues were selected for mutation to Ala during the initial docking, Met101 
and Asp200, as this would increase the size of the pocket opening initially. The ligand 
used for the IFD was sorafenib. 
MD refinement 
The final step for this approach to generating a DFG-out conformation of GSK3- β is to 
use molecular dynamics to assess the stability of the structure over time using 
Schrodinger’s Desmond [115]. The top scoring IFD pose of sorafenib (sorafenib, Figure 
5.2) was taken and the protein ligand complex prepared for dynamics using the Desmond 
system builder. For the system the TIP3P solvation model was used, and the simulation 
box shape was set to orthorhombic. The box volume after minimisation was 530034 Å3, 
and contained 15064 water molecules. 6 Cl- ions were then added to balance the charge. 
Standard equibrilation was used, the length of the simulation was set to 20 ns, the NPT 
ensemble (P=1atm, T=298.15K) was selected, the recording interval was set to 5.0 ps 
and the trajectory was also set to 5.0 ps. Once the simulations had finished, the trajectory 
was visually inspected and analysed to see if the structure of the site varied to a large 
degree. Further analysis was performed using the SID (Simulation Interactions 
Diagrams) tool in Maestro, to see how long the structures took to equilibrate. Once the 
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point of equibrilation had been found, the simulation was cut using a python script 
(manipulate_tr.py, activated using the command shown in Section S1 in the appendix) 
supplied by Schrodinger. The remaining frames (4000) were then clustered into ten 
clusters using the Desmond Trajectory Clustering script available in Maestro, and a 
representative was taken from the most populated cluster to be used as the final DFG-
out structure. 
Docking Details 
Similarly to the DOLPHIN structure, the Prime DFG-out structure was validated using the 
type II sorafenib and BIRB analogues and Glide docking. For the centre of the docking 
grid, the sorafenib molecule was selected. Once the model was validated (c.f. results 
section), it was then used to screen the Biogenics subset database. The settings for both 
dockings were the same as those in section 5.3.2. 
5.3.5 Type II Consensus Scoring  
Once the screening had been completed using the DOLPHIN and Prime/molecular 
dynamics models, the ranks from each of the two complexes were combined in a Simple 
Sum Rank consensus method. This was done using the KNIME workflow shown below 
in Figure 5.5, which had been derived from the original type I inhibitor design workflow 
(Chapter 4). 
Figure 5.5: The KNIME workflow used to combine the .csv files containing the results of 
the screenings 
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5.4 Experimental Details 
5.4.1 Type II Luminosity Assays 
The experimental methods used in the luminosity assays for in vitro validation of the the 
results of the in silico screenings were the same as those from the previous chapter 
(Section 4.4.2) 
5.4.2 Type II IC50 Assays 
Once again, the in vitro IC50 calculations for any compounds that achieved over 50% 
inhibition at 50 μM concentration were carried out by a colleague at the CSIC, using the 
same standard method as that used in the type I assay. 
5.5 Computational Results 
5.5.1 DOLPHIN Model Validation 
The Design of the DOLPHIN Model 
The resultant DOLPHIN structure from the successful protocol outlined in the 
computational details is shown in Figure 5.6 below. 
Figure 5.6: The allosteric pocket and binding site of the DOLPHIN structure, once the 
residues have been removed (right) compared to the regular structure (left). 
As can be seen from Figure 5.6, the deletion of the 5 residues opens up the space at the 
entrance to the allosteric site behind the DFG loop. This opening provides plenty of space 
for a type II ligand to occupy both the hinge region and the allosteric site. As can also be 
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seen from the structure, none of the classical type II interactions will be affected by the 
deletion of these residues, with Asp200, Glu97 and Val135 all still available for hydrogen 
bond interactions. One other noteworthy feature of this structure is the increased overall 
size of the binding site. The deletion of the loop opens up an extra section of the side of 
the cavity (allosteric site), creating a larger space past the DFG loop. This allows 
potential for ligands normally too large for this site (in DFG-in) to be docked into it. 
Results of the DOLPHIN Validation Screening 
Once the initial validation screening was completed for the ligands shown in Figure 5.2, 
the results were compared to those of the experimental inhibition values [56]. These 
results are shown below in Table 5.1. 
Table 5.1: The ranks and Glide scores for the analogues of the known type II inhibitors 
(Figure 5.2) used in the validation screening obtained using the DOLPHIN model, 
compared to the experimental activity taken from the literature [56]. 
Analogue In silico rank Glide score Experimental 
rank a 
Experimental 
IC50  (μM) 
Sorafenib 16 1 -10.26 1 0.86 ± 0.18 
Sorafenib 17 2 -9.70 2 3.3 ± 0.6 
Sorafenib 3 -9.25 3 8.3 ± 0.8 
BIRB 13 4 -7.90 5 >50 
BIRB 14 5 -7.82 5 >50 
BIRB 12 6 -5.93 5 >50 
BIRB 7 -4.84 4 37 
BIRB 15 8 -4.72 5 >50 
 a The ranks of the analogues when ordered by experimental activity 
As can be seen from Table 5.1, the order that the analogues were returned in is highly 
similar to that of the experimental values, with Sorafenib out preforming BIRB. This 
similarity therefore suggests that our model has a high accuracy. The top scoring pose 
of the best performing ligand, sorafenib 16, can be seen below in Figure 5.7. 
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As can be seen from Figure 5.7, the ligand forms three of the four classical interactions 
expected of a type II inhibitor, two hydrogen bonds with Glu97 from the α-C helix, and a 
hydrogen bond with Val135 in the hinge region. It does not form the interaction with 
Asp200, however, this is purely because the angle of the bond between them is too large 
(bond distance is 2.34 Å) for Maestro to recognise it as an interaction. It also forms two 
interesting hydrogen bond interactions with the sidechain NH2s (overall +1 charged) of 
two different Arginine’s (Arg96 And Arg180) at the top of the allosteric pocket, which 
could explain its high Glide score. As the ligand carboxylate is also charged, there will 
be some strong ionic interactions present as well. It can also be seen that the model in 
no way hinders its ability of the ligand to form these interactions, suggesting that this 
model has potential as an alternative to an actual DFG-out structure for virtual screening. 
On top of this, none of the validation analogues docked mainly inside the larger 
DOLPHIN allosteric site, as opposed to the ATP binding site exploiting some extra space 
in the accessible allosteric site (we should note that this was a problem for some of the 
ZINC15 database screened). The agreement between the results from the validation 
screening and the experimental data, along with the demonstration of the ligands ability 
to form all of the classical interactions, led us to decide that the DOLPHIN model would 
be suitable for the final Type II virtual screening.  
Figure 5.7: The top scoring pose for the best performing type II compound in the 
validation screening: Sorafenib 16.  
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5.5.2 Prime/Molecular Dynamics Model Validation 
The Prime Loop refinement DFG-Out Structure 
Once the mutation (Lys103 to Ile) had been made, the Prime loop prediction protocol 
was able to produce a DFG-out structure with 2OW3 with energy -13482.7 kcal/mol at 
rank 71, compared to the energy of the top ranking DFG-in pose -13497.4 kcal/mol. This 
indicates that the salt bridge hydrogen bond between Lys103 and Gln206 was the reason 
that the loop prediction was not initially forming a DFG-out structure in this case. This 
could also possibly explain the lower activity of the Type II inhibitors in Grütter’s paper 
against the human form, as if type II inhibition of the enzyme is dependent on the salt 
bridge being broken, it would occur at a much lower frequency than in the fungal form. 
The salt bridge residue was then restored, and prime was repeated, producing the DFG-
out structure shown below in figure 5.8. 
 Figure 5.8: The DFG-out structure produced by prime loop prediction of the wild-type 
restored structure (right) (-13514.4 kcal/mol rank 70) compared to the top scoring DFG-
in structure from the same calculation. (left) (-13527.7 kcal/mol) 
In figure 5.8, it can be seen that the side chain of Asp200 has been tucked away into the 
new shape of the now flipped out DFG loop, as it is forming a multitude of hydrogen 
bonds with the backbone of the loop (residues 201-204). These interactions, coupled 
with the new shape of the loop, have considerably opened up the entrance to the 
allosteric site, which has created a space for the insertion of type II ligands into the site. 
Also, all of the residues needed for the formation of the classical type II interactions, can 
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be seen to be positioned correctly in this model. Based on this, this structure was 
approved for the next step, which was induced fit docking. 
Induced Fit Docking Refinement Results 
The superimposed DOLPHIN ligand was merged with the DFG-out structure and IFD 
was initiated. The top pose for sorafenib was chosen be used for the molecular dynamics 
simulation is shown below in Figure 5.9. 
Figure 5.9: The top scoring pose for sorafenib 4 (Figure 5.2) produced by induced fit 
docking. Hydrogen bonds with (Residues) are formed, IFD score= -696.940 Glidescore 
= -10.79 
As can be seen from Figure 5.9, the sorafenib inhibitor properly forms all of the classical 
interactions that type II ligands are expected to form, and the residues that line the 
entrance to the allosteric site have rearranged to better accommodate the ligand. 
Molecular Dynamics Simulation Results 
The 20 ns simulation on the top ranked pose from the IFD calculations took 
approximately 5 days on a 3.4 GHz hexacore workstation. Once the molecular dynamics 
simulation was finished, the first step was to find the point of the simulation where the 
system reaches equilibrium, as before this time the simulation is unusable due to the 
structural effects of the equibrilation. This was done using the chart shown below in 
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Figure 5.10. From the chart, the RMSD over time for the backbone and sidechains can 
be seen to stabilise at around 5 ns. Therefore, we cut this section from the simulation 
and began the full analysis on the frames from 5 ns-20 ns. The new trajectory file was 
then analysed again using SID. This produced a variety of charts which are shown below 
in Figure 5.11. 
Figure 5.10: The RMSD over time of the backbone and sidechains of 2OW3 during the 
full 20 ns simulation. The black line indicates the time (5-20 ns) used for analysis 
following equibrilation. 
As can be seen in Figure 5.11, the classical interactions that are expected to occur in 
type II inhibition and that were present in our DOLPHIN model were also shown to be 
present between 90-95% of the duration of the simulation. This strongly indicates that 
this binding mode is stable. As well as this, the flipped DFG loop did not at any point 
during the simulation begin to flip back into the cavity, even with the salt bridge being 
reconstructed during the Prime loop prediction step. There two things combined show 
that the DFG-out conformation that has been created in this model is favourable and can 
interact with ligand molecules in the desired type II manner. Another noteworthy is the 
interaction with the gatekeeper residue, Leu132. As can be seen from the lower 
percentage (just over 50%), this residue does not interact with the ligand strongly enough 
to in anyway interfere with its binding mode in relation to the classical interactions, 
meaning that it would not prevent type II inhibition taking place. 
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Figure 5.11: The Simulation Interactions Diagrams created for the final 15 nanoseconds 
of the molecular dynamics simulation. (A) displays the prevalence of the interactions that 
the ligand forms during the simulation, and (B) shows these interactions relative to the 
2D structure of the ligand and binding site. 
A 
B 
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The frames were then clustered, and the most populated cluster contained 2011 
structures. The representative taken from this cluster is shown below in Figure 5.12. 
Figure 5.12: The representative structure from the most populated molecular dynamics 
frame cluster. 
As can be seen from Figure 5.12, the residues around the ATP binding site and the 
allosteric pocket entrance have adjusted further than they did in the IFD, with the DFG-
out loop also moving to a better binding position. The opening to the allosteric site has 
remained large enough to accommodate the sorafenib molecule, and potentially bind 
larger type II inhibitors also. 
Validation of Prime/Molecular Dynamics Model 
As with the DOLPHIN model, the resultant model of the Prime/Molecular Dynamics was 
validated using the set of sorafenib and BIRB analogues. The results of the docking are 
shown below in Table 5.2. 
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Table 5.2: The ranks and Glide scores for the analogues of the type II inhibitors (Figure 
5.2) used in the validation screening with the MD model, compared to the experimental 
activity. 
Analogue In silico rank Glide score Experimental 
rank a 
IC50 
Sorafenib 17 1 -12.95 2 3.3 ± 0.6 
Sorafenib 4 2 -11.78 3 8.3 ± 0.8 
Sorafenib 16 3 -11.50 1 0.86 ± 0.18 
BIRB 13 4 -10.76 5 >50 
BIRB 3 5 -10.38 4 37 
BIRB 14 6 -9.69 5 >50 
BIRB 12 7 -9.48 5 >50 
BIRB 15 8 -6.22 5 >50 
 a The ranks of the analogues when ordered by experimental activity 
As can be seen from the results, the predicted activity of the analogues puts them in a 
similar order to the experimental values, with one or two exceptions. For example, 
sorafenib 16, the best performing ligand experimentally, is ranked 3rd. This result, 
similarly to the DOPLHIN results, serves to suggest that the designed model will be 
accurate for screening for type II activity. In the screening with sorafenib and BIRB the 
binding mode for these complexes was mainly type II, with the ligands having enough 
space to extend into the allosteric site. All 4 classical interactions, the hydrogen bond 
with Asp200, the two hydrogen bonds with Glu97 and a hydrogen bond with Val135 of 
the hinge region were formed by the top scoring ligands. 
5.5.3 DOLPHIN and Prime comparison 
When compared to the DOLPHIN pose, the final binding position of the sorafenib ligand 
obtained from Prime/Molecular Dynamics model is positioned closer to the centre of the 
allosteric site, whereas the DOLPHIN pose is closer to the DFG Asp200. The most 
plausible reason for this is the increased size of the allosteric pocket near the DFG loop 
in the DOLPHIN model, which allows the section of the ligand inside the site to position 
closer to that side than is possible if the loop was still there. The main interactions that 
appear in the DOLPHIN model, the hydrogen bonds with Glu97, Asp200 and Val135 are 
also present in the new Prime complex too. As can be seen from the chart in Figure 5.11, 
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during the molecular dynamics simulation these interactions were the most prevalent, 
appearing for around 89-95% of the total reaction time. The biggest difference between 
the two models, is that the deletion of the loop in the DOLPHIN model creates a larger 
cavity than the Prime loop prediction. As mentioned above, this has the potential for 
larger sections of the ligand molecules to be docked inside the DOLPHIN allosteric 
pocket. 
5.5.4 DOLPHIN and Prime Virtual Screening Results and Consensus scoring 
Both docking calculations of the filtered ZINC15 biogenic database (27,286 ligands) 
using both DFG-out models of GSK-3β finished unhindered, and the results were 
combined using the Simple Sum Rank consensus scoring method (KNIME workflow in 
Figure 5.5). From the top 200, 65 compounds had Glide scores similar to the sorafenib 
analogues (≤ -10 for Prime/Molecular Dynamics model and ≤ -9 for DOLPHIN model) 
were chosen for further consideration. This score cut-off was chosen as the sorafenib 
compounds received low micromolar IC50 values, and therefore compounds with similar 
in silico scores have the potential for similar in vitro scores as well. 
5.5.5 Type II Compound Selection 
20 compounds from the top 65 were purchased, as well as sorafenib itself. Sorafenib 
allowed comparison to the experimental IC50 from in Grütter’s paper and was therefore 
used as a benchmark. Of these compounds, 20 were purchased from Analyticon 
(ZINC000008299930, ZINC000004259649, ZINC000008297322, ZINC000008623925, 
ZINC000004200864, ZINC000004235515, ZINC000096112349, ZINC000096112343, 
ZINC000096112276, ZINC000096112042, ZINC000096112517, ZINC000004200873, 
ZINC000004200863, ZINC000096112052, ZINC000096112247, ZINC000096112049, 
ZINC000096112048, ZINC000096112254, ZINC000008635710 and 
ZINC000096112199), and sorafenib was purchased from Stratech. The structures of 
these compounds (1-21) are all shown in Figure 5.13.  
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Figure 5.13: The structures of all of the type II compounds chosen for biological testing. 
1) Sorafenib 2) ZINC000008299930, 3) ZINC000004259649, 4) ZINC000008297322, 5) 
ZINC000008623925, 6) ZINC000004200864, 7) ZINC000004235515, 8) 
ZINC000096112349, 9) ZINC000096112343, 10) ZINC000096112276, 11) 
ZINC000096112042, 12) ZINC000096112517, 13) ZINC000004200873, 14) 
ZINC000004200863, 15) ZINC000096112052, 16) ZINC000096112247, 17) 
ZINC000096112049, 18) ZINC000096112048, 19) ZINC000096112254, 20) 
ZINC000008635710 and 21) ZINC000096112199 
These compounds were chosen based on their ranks and scores, as well as their various 
interactions, with an emphasis on the previously discussed classical type II interactions 
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first. This was followed by an investigation of any extra interesting interactions that the 
ligands form, for example an extra hinge region interaction or a π-π stacking interaction 
with the phenyl group of the Phe201 from the DFG loop, which could serve to stabilise 
the DFG-out composition. Table 5.3 below shows the consensus ranks of the 20 
compounds, as well as their ranks and scores with each model. 
Table 5.3: The consensus ranks and predicted data of the 21 compounds chosen 
Title a DOLPHIN 
Rank 
DOLPHIN 
Gscore 
MD 
Structure 
Rank 
MD 
Structure 
Gscore 
Simple 
Sum Rank 
ZINC00000829993
0 Compound 2 
17 -9.174 19 -10.487 7 
ZINC00000425964
9 Compound 3 
37 -8.906 20 -10.486 11 
ZINC00000829732
2 Compound 4 
181 -8.331 13 -10.605 30 
ZINC00000862392
5 Compound 5 
158 -8.398 16 -10.578 29 
ZINC00000420086
4 Compound 6 
4 -9.623 457 -9.223 55 
ZINC00000423551
5 Compound 7 
370 -8.002 71 -10.112 54 
ZINC00009611234
9 Compound 8 
21 -9.125 14 -10.599 6 
ZINC00009611234
3 Compound 9 
12 -9.314 34 -10.319 9 
ZINC00009611227
6 Compound 10 
64 -8.781 24 -10.444 14 
ZINC00009611204
2 Compound 11 
29 -8.971 50 -10.224 13 
ZINC00009611251
7 Compound 12 
183 -8.323 96 -10.003 44 
 94 
 
ZINC00000420087
3 Compound 13 
2 -9.838 4 -11.017 2 
ZINC00000420086
3 Compound 14 
195 -8.296 40 -10.271 35 
ZINC00009611205
2 Compound 15 
39 -8.888 1 -11.244 8 
ZINC00009611224
7 Compound 16 
56 -8.808 15 -10.598 12 
ZINC00009611204
9 Compound 17 
27 -9.007 3 -11.023 5 
ZINC00009611204
8 Compound 18 
13 -9.313 7 -10.794 4 
ZINC00009611225
4 Compound 19 
6 -9.588 10 -10.703 3 
ZINC00000863571
0 Compound 20 
439 -7.912 42 -10.269 56 
ZINC00009611219
9 Compound 21 
24 -9.081 25 -10.435 10 
a c.f. Figure 5.13 
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5.6 Biological Results 
5.6.1 Type II Luminosity Binding Assay Results 
The results of the type II luminosity assay can be seen below in Table 5.4. 
Table 5.4: The results of the in vitro luminosity assay for the selected type II inhibitors, 
along with their purities, molecular weights and any calculated IC50 values. 
Type 2 
Inhibitors 
Zinc code and 
Compound Number 
Mw (Da) Purity % Inhibition IC50 μM 
Sorafenib - 464.831 95% 64.54±1.59 32.64 ± 
0.76 µM 
NAT6-
321961 
ZINC000008299930 
Compound 2 
515.492 100.000 99.012 74.45±2,37 26.96 ± 
1.77 µM 
NAT6-
297729 
ZINC000004259649 
Compound 3 
543.55 96.086 86.454 7.17±2,27 - 
NAT6-
321324 
ZINC000008297322 
Compound 4 
515.429 99.389 93.636 89.87±2,72 9.75 ± 
2.2 µM 
NAT16-
353088 
ZINC000008623925 
Compound 5 
442.479 100.000 92.034 25.54±1,06 - 
NAT3-
155416 
ZINC000004200864 
Compound 6 
577.592 99.574 87.958 5.64±3,17 - 
NAT6-
270085 
ZINC000004235515 
Compound 7 
543.498 100.000 100.000 41.78±1,83 - 
NAT37-
534362 
ZINC000096112349 
Compound 8 
410.493 100.000 97.712 2.40±2,71 - 
NAT37-
534352 
ZINC000096112343 
Compound 9 
354.429 100.000 98.840 4.69±1,97 - 
NAT37-
534198 
ZINC000096112276 
Compound 10 
406.461 100.000 91.753 12.71±1,69 - 
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NAT37-
532879 
ZINC000096112042 
Compound 11 
358.348 97.249 86.062 2.01±0,93 - 
NAT41-
514998 
ZINC000096112517 
Compound 12 
380.404 100.000 92.403 0.65±2,88 - 
NAT3-
155435 
ZINC000004200873 
Compound 13 
568.725 97.665 92.216 5.30±1,71 - 
NAT3-
155413 
ZINC000004200863 
Compound 14 
552.582 100.000 100.000 4.80±0,90 - 
NAT37-
532925 
ZINC000096112052 
Compound 15 
408.355 100.000 94.923 13.97±1,26 - 
NAT37-
534097 
ZINC000096112247 
Compound 16 
418.394 100.000 98.341 7.20±1,78 - 
NAT37-
532911 
ZINC000096112049 
Compound 17 
407.367 100.000 92.125 19.18±1,03 - 
NAT37-
532910 
ZINC000096112048 
Compound 18 
437.393 100.000 96.465 18.96±1,62 - 
NAT37-
534136 
ZINC000096112254 
Compound 19 
471.476 98.607 92.786 32.60±1,62 - 
NAT13-
339804 
ZINC000008635710 
Compound 20 
424.614 100.000 90.187 0.80±0,63 - 
NAT37-
534009 
ZINC000096112199 
Compound 21 
378.451 99.717 95.230 13.76±3,42 - 
  
As can be seen from Table 5.4, there were three type II compounds from the 21 including 
sorafenib (64.54%), ZINC000008299930 (compound 2) (74.45%) and 
ZINC000008297322 (compound 4) (89.87%) that received percentage inhibition values 
of over 50%. The rest of the compounds ranged from less than 1% inhibition to 41%. 
The binding modes of these three molecules are shown below in Figure 5.15. 
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Figure 5.14: The binding modes, both in 2D and 3D of ZINC000008299930 (A) and 
ZINC000008297322 (B). 
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As can be seen in Figure 5.14, both of these inhibitor molecules form the classical 
interactions for type II compounds, a hydrogen bond with the backbone NH of Asp200, 
2 hydrogen bonds with the sidechain COO- of Glu97 on the α-C helix. They also form the 
hydrogen bond with the backbone C=O Val135 in the hinge region, but this is not 
displayed by Maestro once again because of the angle. Both of these inhibitors also form 
an additional with the hinge region, a hydrogen bond with the backbone of Asp133. 
Compound 2 and compound 4 share multiple common structural features, for example 
they both contain an interesting fused hexahydrofuro-furan ring structure. The 
compounds high similarity means that the large difference in their activity can be 
potentially attributed to the positioning of the OMe group on the hinge region end 
aromatic ring of the ligand molecule. In compound 2, the OMe is ortho substituted 
whereas in compound 4 it is para substituted. This is the only major difference between 
these two structures, and therefore this positioning is potentially very important for 
potency. 
5.6.2 Type II IC50 Results 
As the only compounds with percentage inhibition values of over 50% sorafenib, 
compound 2 and compound 4 were all tested for their experimental IC50 values. 
Sorafenib obtained an IC50 value of 32.64 ± 0.76 µM, which was derived from the graph 
below in Figure 5.15. 
Figure 5.15: The graph used to calculate the in vitro IC50 of Sorafenib, with % activity 
plotted against concentration. 
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While the IC50 is much higher than the value obtained in Grütter’s publication, provided 
all other ligands are assayed in identical conditions to this it can provide a solid 
benchmark potency with which to compare the other values. 
The second ligand, compound 2 obtained an IC50 value of 26.96 ± 1.77 µM, derived from 
the graph below in Figure 5.16. 
Figure 5.16: The graph used to calculate the in vitro IC50 of compound 2 by plotting % 
activity against concentration.  
The IC50 of this compound is higher than that of sorafenib. This is possible due to its 
increased amount of hinge region interactions, which could explain the higher potency 
of this ligand over that of Sorafenib. 
The final inhibitor, compound 4 produced an IC50 value of 9.75 ± 2.2 µM, which was 
obtained using the graph below in Figure 5.17. 
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Figure 5.17: The graph with % activity of GSK-3β plotted against concentration of 
compound 4, used to calculate the in vitro IC50. 
This ligand also received an IC50 lower than that of sorafenib, receiving the lowest IC50 
out of the three inhibitors. It also forms an extra hinge region interaction compared to 
sorafenib, further confirming that this causes the increase in potency. 
Overall, all three inhibitors received relatively good IC50 values. Both of the ligands 
selected in the in silico screening, compound 2 and compound 4, achieved potencies 
higher than that of sorafenib. As the structures of these two ligands are very similar, the 
only real difference being the position of the OMe group on the aromatic ring at the hinge 
region end of the molecule, it can be deduced that this difference is the main reason for 
the large disparity between their activities. For compound 2, the OMe group is ortho 
substituted whereas in compound 4 the OMe group is para. These IC50 results also 
suggest that the binding mode of these inhibitor compounds is indeed type II. This is due 
to the fact that due to their larger size and flexibility, these compounds would be unable 
to achieve type I IC50 values lower than that of type I compound 6 (section 4.5). Therefore, 
it is reasonable to conclude that the binding modes of these compounds is indeed type 
II. Also, due to the fact that the IC50 of sorafenib is a lot higher than the experimental 
value Grütter obtained, it is possible that the values for the other two inhibitors are 
potentially equally high, and could be a lot more potent than is shown in this study. 
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5.7 Conclusion 
In this project, we developed two different type II DFG-out models, both of which were 
shown to be accurate at predicting the binding modes of type II ligands by the validation 
screenings of the sorafenib and BIRB analogues. The DOLPHIN model produced had a 
larger allosteric cavity than normal, due to the deletion of the 5 residues, and this caused 
type II ligands to bind closer to the DFG Asp200 residue. However, the model was still 
able to form all of the classical interactions, and the validation results it produced were 
quite similar to the experimental results. The Prime/Molecular Dynamics structure on the 
other hand, has a smaller allosteric site, due to the fact that the loop was still present. 
Once the mutation of the salt bridge was applied, the loop flipped to the DFG-out position 
without hindrance, and produced a model that could be refined into a type II structure. 
The IFD docking successfully refined this structure, repositioning the residues near the 
opening of the allosteric site around the superimposed ligand, increasing the size of the 
opening of the pocket and further stabilising the position of the ligand. Through the 
molecular dynamics, this structure was shown to be stable, and the classical interactions 
were present for over 90% of the simulation. This model also performed well during the 
validation screenings, returning values that were very close to the experimental results 
from the paper by Grütter et al, with the exception of sorafenib 16, which ranked 3rd 
instead of 1st. The next step, the screening of the ZINC15 Biogenic subset database was 
completed without any problems, and the results were found to combine well into a 
simple sum rank consensus score. The top compounds of the consensus scored 
database almost all formed the four classical interactions, with some of the compound 
missing one of the hydrogen bonds with Glu97 or the hydrogen bond with Val135. The 
final selected 20 compounds were all extremely similar in general structure and shape 
to sorafenib, which shows that this geometry is preferential for type II inhibitors. The type 
II ligands gave a very wide variety of percentage inhibitions, ranging from as low as 0.6% 
to upwards of 80% at 50 μM. The three best performing ligands in this assay were: 
sorafenib (64.54%), compound 2 (74.45%) and compound 4 (89.87%). The IC50 value 
for sorafenib was 32.64 ± 0.76 µM, compared to the 8.3 µM value from Grütter. While 
the value we obtained is much higher, as long as the other type II inhibitors are assayed 
in identical conditions, this value can provide a solid benchmark potency that can be 
used to assess the potency of the other two inhibitors. It also presents the possibility that, 
as this value is so much higher than that of Grütter, the IC50 values for the other 
compounds could also be higher than normal, and therefore our type II inhibitors are 
potentially even more potent that their values would suggest. In effect, compound 2 
(26.96 ± 1.77 µM) and compound 4 (9.75 ± 2.2 µM) were both shown to be more potent 
than sorafenib. As their structures have the same core scaffold, this result suggests that 
the groups that they have, the hexahydrofuro-furan fused ring structure, the pyrimidine 
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ring near the hinge and the terminal OMe group are all potentially conducive to the 
potency of the inhibitors. The only difference in structure is the position of the OMe group, 
for compound 2 (26.96 ± 1.77 µM) the group is ortho substituted and for compound 4 
(9.75 ± 2.2 µM) the OMe is para substituted. This, therefore, indicates the difference 
between the ortho and para substitution caused the 17 µM difference in their IC50 values. 
Their IC50 values also serve to indicate that their binding mode is indeed type II, as these 
ligands are too large and flexible, with too few hinge region interactions to compensate, 
to achieve such a high type I potency. Based on the results of this project, the next step 
could be to search the top part of the consensus ranked database for various compounds 
with structures similar to those of the two potent inhibitors, to see if any other groups 
could potentially be used to increase their potency. It would also be beneficial to further 
explore the reason why the para substituted OMe performed so much better than the 
ortho OMe, as this could give new insight into the optimisation of binding ligands to this 
area of the ATP binding site, regardless of the type of inhibition. In conclusion, two 
designed DFG-out GSK-3β type II structures were used to screen a database of natural 
product molecules and successfully identified two novel potential type II inhibitors for 
further study. Additionally, other ligands from the screening can be selected for further in 
vitro validations. 
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Chapter 6: Conclusion 
There were four overall aims for this project outlined in section 1.5. In this conclusion I 
will address these four objectives, and how they were met. 
1) To investigate and design novel type I (ATP binding site) and type II (activation loop 
out) inhibitors of GSK-3β. 
Upon the completion of this project, we have successfully designed inhibitors of GSK-3β 
of both types, with IC50 values in the micromolar range. These inhibitors were designed 
using a variety of other techniques, as set out in the subsequent objectives, and active 
inhibitor compounds were selected and biologically validated for each type. 
2) To apply a consensus scoring method involving a virtual screening with 4 different 
programs, GOLD, Glide-SP, Glide-XP and AutoDock to a large database taken from the 
ZINC docking database website (www.ZINC15.org) [33].  
For the development of potential type I ATP binding site inhibitors, an in silico virtual 
screening docking method based on consensus scoring was devised. This was done 
using a benchmarking screening to assess various different combinations of docking 
programs, by screening an active/decoy ligand set containing 30 known active 
compounds, 189 real inactive compounds, and 1800 decoy inactives generated using 
DUDE[98]. A series of statistical metrics were employed to assess the accuracy of these 
different combinations, including the enrichment factor (EF), modified enrichment factor 
(EF’) and BEDROC. The final consensus method that was chosen was a combination of 
Glide-SP and –XP, AutoDock Vina and GOLD ASP, with a simple sum ranking method 
as the statistical values produced are significantly higher compared to those of the 
individual programs. Pharmacophore models were applied to create an extra set of data 
with to improve the overall accuracy of the results. Once the virtual screening had 
finished, all of the information generated during the preparation of the database and the 
creation of the method was used to select 10 final compounds, which are diverse but 
also share common features conducive to binding. 
3) To design two novel type II structures of GSK-3β, using different computational 
methods, molecular dynamics and DOLPHIN docking[34], and to use them to screen a 
database in silico. The results for these two models are to be combined using a 
consensus scoring method. 
For the investigation of type II inhibition of GSK-3β, two different type II DFG-out models 
were developed. The first model was created using DOLPHIN docking, which involved 
the deletion of 5 residues (201-205). This model was found to have a larger allosteric 
site due to the deletion, and this caused type II ligands to bind closer to the DFG Asp200 
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residue. This difference in the size of the site however did not affect the models ability to 
form the classical type II interactions. The second model was designed using a 
combination of Prime loop refinement, induced fit docking and molecular dynamics. This 
produced a structure with a DFG loop in the out position, with a smaller allosteric pocket, 
due to the fact that the loop was still present. Both models were then validated using a 
selection of type II ligands and their corresponding experimental data. Once both models 
were validated, they were the used to screen the Biogenic subset database (27,286 
Compounds) taken from ZINC15[33]. The two resultant ranks for each of the compounds 
were combined into a simple sum consensus score rank. It was noted that most of the 
compounds at the top consensus scored database formed the four classical type II 
interactions. Also many of the compounds at the top of the database were similar in 
general structure and shape to sorafenib, showing that this type of geometry is 
preferential for type II inhibitors. From this consensus ranked database, 20 compounds 
were selected for biological validation. 
4) To select the top compounds from both the type I and type II screenings for 
transportation to the CSIC in Madrid on an Erasmus+ placement where they will have 
their IC50 values tested in vitro 
The first assay involved the use of a luminescence reaction involving ATP to calculate 
the percentage inhibition of the inhibitors. Overall, 6 of the 10 type I inhibitors produced 
a percentage inhibition of over 20% at 50 μM, with one of the compounds, type I 
compound 6 (ZINC000072152229) even receiving a value as high as 74.58%. The type 
II compounds produced a large range of percentage inhibitions in the first assay, with 
one value as low as 0.6% at 50 μM and another being upwards of 80%. The three ligands 
that performed the best in this assay were: sorafenib (64.54%), compound 2 
(ZINC000008299930) (74.45%) and compound 4 (ZINC000008297322) (89.87%). In the 
second assay, the IC50 of type I compound 6 was investigated, as it was the only inhibitor 
with a percentage inhibition over 50%. The IC50 of this compound was found to be 24.69 
± 0.73 μM. Due to compound 6 mainly binding via the hinge region, it was expected to 
have a relatively high potency; however, it was noticed that it also forms an ionic 
interaction with Asp200 at the back of the ATP binding site, which is likely to greatly 
increase its potency. The ligand also only formed one of the various selective interactions 
with Phe67. The IC50 values of the type II compounds, Sorafenib, compound 2 and 
compound 4 were; 32.64 ± 0.76 µM, 26.96 ± 1.77 µM and 9.75 ± 2.2 µM respectively. 
As the structures of compound 2 and compound 4 are considerably similar. The only 
difference in their structures is the position of the OMe group, this difference between 
the ortho and para substitution is implicated heavily in the 17 µM difference in their IC50 
values. 
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Appendix 
 
S1: List of Commands used 
Ubuntu terminal commands in this project: 
-Removal of the additional sections Goldmine adds to the names of the actives  
:%s/(phrase)/(newphrase)/g 
-Running of ZINC tranche download files 
Chmod u+x (filename) 
-Then to run the executable: 
./(filename) 
-Moving all of the SMILES patterns downloaded from ZINC into one file: 
cat input>output 
-Removing unwanted lines from the SMILES pattern files before random selection: 
find . –type f –print0 |xargs -0 sed –I /zinc-id/d 
-Selecting 500,000 random lines from the newly combined file: 
shuf –n 500,000 input>output 
-Trimming the length of the Molecular dynamics trajectory: 
$SCHRODINGER/run –FROM desmond manipulate_trj.py (original trajectory .cms file) 
(new filename) “output- directory-name” 
Excel formulae used in this project: 
Simple sum: 
=A2+B2+C2+D2 
The exclusion of the worst rank: 
=MAX(range,cell) 
The calculation of the Deprecated sum rank: 
=E2-F2 
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S2: Data produced by the consensus scouring process for the type I and type II studies 
Table S.1: The Consensus ranks and other values generated for the top 200 compounds 
from the type I virtual screening 
Title Consensus 
Rank 
SP 
Rank 
XP 
Rank 
ASP 
Rank 
Vina 
Rank 
MW 3Pt 4Pt 5Pt 
ZINC000450524273 198 1095 308 15094 1442 321.424 1 0 0 
ZINC000071967954 94 574 4766 6278 628 340.381 1 0 0 
ZINC000096131333 50 5033 1777 1098 1172 341.455 1 0 0 
ZINC000289288811 31 656 2180 2238 2449 369.398 0 0 0 
ZINC000020892148 197 2375 12221 2732 598 387.858 1 1 0 
ZINC000072152229 24 94 1557 926 3992 310.401 1 0 0 
ZINC000262476404 122 37 397 8220 5804 314.389 1 0 0 
ZINC000288905010 77 40 292 604 10249 325.293 1 0 0 
ZINC000294563530 180 161 6062 8455 2471 328.385 0 1 0 
ZINC000278292143 40 31 1042 5593 1767 343.403 0 0 0 
ZINC000452372528 171 2197 608 9017 5052 305.275 0 0 0 
ZINC000057813806 74 483 3697 2922 3959 320.393 1 0 0 
ZINC000125990757 108 4538 1254 5639 2207 321.378 0 0 0 
ZINC000281451553 156 2524 8990 2267 2409 327.281 1 0 0 
ZINC000272945127 195 615 14990 514 1756 331.324 0 0 0 
ZINC000123763813 83 3145 440 7835 182 332.404 0 0 0 
ZINC000065164461 200 11976 3054 2316 827 339.344 0 1 0 
ZINC000339309810 76 1484 9217 449 14 340.329 0 0 0 
ZINC000370567443 105 447 4242 6906 1924 341.308 1 1 0 
ZINC000262042192 181 10481 2209 3593 921 347.419 0 0 0 
ZINC000186647315 127 275 819 3811 9713 359.445 1 0 0 
ZINC000030030588 177 887 1839 13895 441 360.458 1 1 0 
ZINC000268128830 125 722 7717 4785 1258 281.316 1 0 0 
ZINC000199720928 66 63 592 8695 911 307.247 0 1 0 
ZINC000127453735 75 905 1022 5068 4113 310.373 1 1 0 
ZINC000373427455 175 262 3206 11557 1934 312.368 0 0 0 
ZINC000185165653 79 69 1244 9942 186 324.382 0 0 0 
ZINC000028406051 92 80 173 7889 3918 327.816 1 1 0 
ZINC000171617571 147 4676 5844 4959 263 330.388 0 0 0 
ZINC000155200372 16 270 925 3248 1196 336.436 1 1 0 
ZINC000459356124 22 1794 2617 1024 745 338.384 0 0 0 
ZINC000337570093 85 555 2141 2899 6184 340.424 1 0 0 
ZINC000093642388 54 482 4458 1365 2968 356.424 1 0 0 
ZINC000020540831 1 2 24 38 159 375.396 1 0 0 
ZINC000189195311 98 758 2601 7866 1692 395.547 1 0 0 
ZINC000292555245 118 3945 1826 3664 4561 296.295 1 0 0 
ZINC000333894224 196 1970 7882 1913 6158 309.413 1 0 0 
ZINC000330030716 113 1513 405 10866 962 312.414 1 0 0 
ZINC000369213404 49 1295 1472 1292 4880 313.297 0 0 0 
ZINC000059228950 97 2279 6673 2158 1565 314.343 0 0 0 
ZINC000284431465 158 1946 6758 5071 2424 324.425 0 0 0 
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ZINC000459377677 51 1731 417 4247 2728 325.41 1 0 0 
ZINC000338569359 26 560 2656 1612 1851 335.38 0 0 0 
ZINC000423021568 131 1387 1157 10484 1962 336.433 0 0 0 
ZINC000328691701 111 243 3327 4001 6113 337.427 1 1 0 
ZINC000095965527 130 2425 3017 2338 7087 341.35 0 0 0 
ZINC000340416229 179 8478 728 4411 3463 344.36 1 0 0 
ZINC000368168772 95 2674 7932 1555 286 344.415 0 0 0 
ZINC000183269073 73 1207 218 8642 899 345.416 1 0 0 
ZINC000023126377 172 4728 5670 5887 605 346.446 0 0 0 
ZINC000330176611 104 3074 2311 3474 4625 347.324 0 0 0 
ZINC000248069775 164 2611 844 11352 1717 349.388 1 1 0 
ZINC000331884986 14 103 1078 2418 1833 364.394 1 0 0 
ZINC000008249063 18 3899 1112 782 51 406.501 1 1 0 
ZINC000294625147 152 5 640 5131 10314 292.285 1 1 0 
ZINC000285351235 65 433 3374 3818 2432 309.41 1 0 0 
ZINC000372806516 21 87 34 3241 2633 324.382 1 1 0 
ZINC000580212021 58 215 44 4191 5151 325.413 1 0 0 
ZINC000332282303 47 2519 2584 1271 2500 334.368 1 1 0 
ZINC000125697807 144 104 147 11113 4108 344.431 0 0 0 
ZINC000067679223 2 138 794 31 624 356.429 0 0 0 
ZINC000159432235 20 68 50 282 5542 364.403 0 0 0 
ZINC000263619162 80 7016 1538 2978 46 366.849 1 1 0 
ZINC000067820131 6 287 463 1714 252 379.504 1 1 0 
ZINC000364094692 112 4054 1551 1745 6376 296.295 0 0 0 
ZINC000288214615 12 418 651 1538 2446 324.425 0 0 0 
ZINC000279014268 93 4622 464 3880 3279 324.425 1 1 0 
ZINC000261732557 185 3056 2097 7936 4335 326.397 1 0 0 
ZINC000362869142 199 471 3492 12661 1372 328.37 1 0 0 
ZINC000286076105 37 1154 1365 1162 4520 328.413 0 0 0 
ZINC000343735908 101 408 772 1508 10617 329.33 1 1 0 
ZINC000092013697 110 2806 410 3373 7067 333.362 1 0 0 
ZINC000052856983 141 876 1158 9373 3946 335.405 0 0 0 
ZINC000301167184 148 3332 4318 4734 3381 337.467 0 0 0 
ZINC000370730930 71 250 512 1333 8494 339.371 1 1 0 
ZINC000368382090 38 665 1971 813 4871 339.399 1 0 1 
ZINC000072322171 35 2332 322 2196 2934 339.436 0 0 0 
ZINC000264929496 170 10501 1400 564 4358 344.723 1 0 0 
ZINC000372407284 25 48 192 5988 398 348.447 0 1 0 
ZINC000020024316 23 178 1212 2181 2841 350.367 0 0 0 
ZINC000009461191 78 1221 1922 5487 2800 351.346 1 1 0 
ZINC000179744911 17 1169 64 306 4203 351.407 0 0 0 
ZINC000071753872 129 492 7297 1509 5354 352.356 1 1 0 
ZINC000271290060 114 44 615 3126 10004 355.457 0 0 0 
ZINC000290893683 86 295 2460 3029 6035 355.826 1 1 0 
ZINC000377434377 159 151 800 12677 2652 358.439 1 0 0 
ZINC000270370414 90 5057 629 3131 3219 358.87 0 0 0 
ZINC000377586544 166 1829 6018 5125 3647 368.435 1 1 0 
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ZINC000292820293 70 2710 1020 798 6054 371.402 0 0 0 
ZINC000091894386 9 127 25 146 2963 371.413 1 0 0 
ZINC000046053995 67 1419 210 7120 1557 375.485 1 0 0 
ZINC000019497338 162 4918 1055 8873 1526 382.505 1 0 0 
ZINC000263617294 3 1138 427 21 95 388.803 1 1 0 
ZINC000019574126 167 8906 1636 848 5248 400.541 0 1 0 
ZINC000072393713 4 493 446 748 88 406.502 0 0 0 
ZINC000002738092 143 6271 8975 32 147 463.474 1 1 0 
ZINC000071315326 184 584 3715 1390 11647 301.434 0 0 0 
ZINC000257265440 39 22 4893 251 3188 334.423 1 1 0 
ZINC000355536096 7 1050 649 142 990 347.419 1 1 0 
ZINC000097505396 42 2068 1620 2705 2179 356.424 1 1 1 
ZINC000273149682 89 4308 3641 2281 1757 357.411 1 0 0 
ZINC000048367002 102 4880 1353 4962 2115 307.394 1 1 0 
ZINC000237440882 53 628 3353 1009 4281 308.385 1 1 0 
ZINC000272590346 87 927 5376 2342 3237 312.414 0 0 0 
ZINC000255369784 57 932 1671 3755 3185 322.406 1 0 0 
ZINC000122196365 163 2463 46 2109 11860 323.397 1 0 0 
ZINC000559958970 136 1350 376 6699 6749 328.337 1 0 0 
ZINC000422946798 124 516 364 2429 11171 330.404 1 1 0 
ZINC000343859200 192 6353 4855 4703 1871 331.364 1 0 0 
ZINC000451290903 139 382 5633 4249 5048 331.389 1 0 0 
ZINC000436385819 45 3806 3066 789 1034 332.447 1 0 0 
ZINC000026875067 88 1074 5035 542 5281 337.383 0 0 0 
ZINC000527996390 194 5782 388 6592 5109 338.405 1 1 0 
ZINC000487549914 64 779 3576 605 5084 339.36 1 0 0 
ZINC000122153639 30 2278 1003 1092 3014 343.4 1 0 0 
ZINC000332477740 193 3397 5453 5553 3411 344.416 1 0 0 
ZINC000420187294 160 414 2185 12332 1417 346.379 1 0 0 
ZINC000216621950 82 783 4169 4338 2301 346.431 0 0 0 
ZINC000337214634 120 314 611 120 13297 347.419 1 1 0 
ZINC000354749349 63 1511 2634 4462 1361 348.831 1 0 0 
ZINC000281583613 140 3815 4449 6876 192 350.34 1 0 0 
ZINC000275642118 48 2039 950 2670 3258 350.422 1 1 0 
ZINC000091165972 174 1321 92 10150 5392 350.823 1 1 0 
ZINC000270976355 72 2022 190 2827 5847 357.408 1 0 0 
ZINC000064758501 84 565 4001 237 6973 364.449 1 0 0 
ZINC000270482066 8 234 76 1463 1263 367.493 0 0 0 
ZINC000261665889 96 1360 638 6169 4333 371.478 0 0 0 
ZINC000020292321 69 1200 1293 1185 6882 375.445 0 0 0 
ZINC000095378901 149 2097 13456 88 181 378.47 1 0 0 
ZINC000095500815 10 264 600 1699 853 385.465 0 0 0 
ZINC000020115971 56 2888 3091 630 2842 399.507 1 1 0 
ZINC000072359421 128 10313 3062 113 1144 413.924 1 1 0 
ZINC000358060689 61 206 1427 3326 4804 330.386 1 0 1 
ZINC000072469924 44 1239 1823 1573 4005 379.504 0 0 0 
ZINC000067714443 123 12487 1387 141 453 381.409 1 1 0 
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ZINC000344434637 46 2060 1831 1350 3481 326.37 1 1 0 
ZINC000370688320 132 285 2108 1685 10961 327.816 1 1 0 
ZINC000238074825 168 4791 4102 4612 3171 334.42 1 0 0 
ZINC000188429278 146 3144 5938 873 5679 340.424 1 1 0 
ZINC000292435054 119 1220 2024 2962 7948 341.409 1 0 0 
ZINC000275492132 191 233 434 1119 15994 343.403 1 1 0 
ZINC000036753814 126 960 387 10342 2881 343.425 1 0 0 
ZINC000423993887 169 5965 5651 3138 1967 347.847 0 0 0 
ZINC000492277385 100 7260 1723 545 3772 348.407 1 0 0 
ZINC000179629498 34 195 150 4278 3093 348.447 0 0 0 
ZINC000191806771 68 4859 3014 1931 662 348.447 0 0 0 
ZINC000040118557 176 246 2257 2942 11585 355.479 0 0 0 
ZINC000095372670 109 735 433 5395 7079 356.467 1 1 0 
ZINC000361218831 91 1549 855 7056 2583 360.498 1 0 0 
ZINC000275119766 117 1816 6641 1112 4417 370.328 1 0 0 
ZINC000103449421 161 6160 2511 3621 4059 370.45 1 0 0 
ZINC000068202913 52 996 1228 3061 3983 374.482 0 0 0 
ZINC000065531780 121 4745 8796 48 830 391.429 1 0 1 
ZINC000055254089 99 4748 3979 252 3952 395.442 0 0 0 
ZINC000072372430 116 2328 9133 917 1585 397.559 1 0 0 
ZINC000095356616 15 562 234 2556 2167 398.504 1 0 0 
ZINC000013692664 41 4863 3484 128 36 400.433 0 0 0 
ZINC000020519057 29 2153 2107 230 2847 411.503 1 0 1 
ZINC000023844492 133 11854 749 401 2083 432.521 1 0 0 
ZINC000023560369 103 2291 9900 663 606 452.527 1 0 0 
ZINC000041585043 28 5476 938 598 59 461.492 1 1 0 
ZINC000013626739 36 5955 1653 172 107 464.492 1 0 1 
ZINC000024767799 81 9171 1602 471 334 471.353 1 0 0 
ZINC000340524328 13 1037 538 378 3464 330.336 1 0 1 
ZINC000187804366 11 2018 175 717 901 370.407 1 1 0 
ZINC000431476232 155 936 4773 1739 8736 310.37 1 1 0 
ZINC000275640860 107 591 114 7028 5894 321.421 1 1 0 
ZINC000289852136 187 1606 8959 2352 4545 322.409 1 0 0 
ZINC000123797419 190 2215 2036 1611 11866 330.404 1 1 0 
ZINC000414381194 178 2790 1175 1998 11101 339.415 1 0 0 
ZINC000134272869 60 642 347 4628 4124 340.467 1 1 0 
ZINC000013998761 165 626 273 4134 11514 342.824 1 1 0 
ZINC000190622496 106 3536 3861 1921 4245 343.4 1 0 0 
ZINC000421188100 134 2575 10300 816 1421 343.4 1 1 0 
ZINC000152216644 154 2220 14 4481 9461 344.431 1 0 0 
ZINC000364190188 151 8464 2650 72 4836 346.434 1 0 0 
ZINC000023989544 55 2460 1683 3657 1539 363.458 1 1 0 
ZINC000246977920 43 3015 790 521 4305 372.466 1 1 0 
ZINC000013596742 5 836 698 419 315 373.497 0 0 0 
ZINC000044443334 145 5912 5126 578 3936 380.464 1 0 0 
ZINC000020235952 182 7601 9600 29 81 389.496 1 0 0 
ZINC000027365919 189 3606 13475 14 608 391.518 0 0 0 
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ZINC000072371357 137 7839 275 71 7010 410.438 1 1 0 
ZINC000015734989 33 686 3727 1654 1523 448.572 1 0 0 
ZINC000016393552 115 7283 398 1043 5236 461.021 0 0 0 
ZINC000032903749 153 9853 6038 123 119 462.547 1 1 1 
ZINC000189024853 59 1713 52 6967 904 322.406 1 1 0 
ZINC000279814647 32 237 933 3132 3283 349.475 1 0 0 
ZINC000014971305 157 325 669 3687 11516 339.393 1 0 0 
ZINC000097568925 62 43 30 436 9311 353.463 0 0 0 
ZINC000363085131 188 2849 55 3730 10853 372.509 1 0 0 
ZINC000012718228 186 9367 1877 997 5218 382.505 1 0 1 
ZINC000011911811 173 10307 4557 51 2032 441.959 0 0 0 
ZINC000019793351 19 2820 2526 411 116 453.583 0 1 0 
ZINC000034681715 150 3717 9283 85 2876 466.966 1 1 0 
ZINC000014532622 183 13359 3622 121 228 467.61 1 0 0 
ZINC000134487938 135 366 212 2627 11922 336.433 1 1 0 
ZINC000019848477 27 2523 776 3421 236 376.497 1 0 0 
ZINC000055171898 142 8197 2970 244 3951 377.442 1 1 0 
ZINC000012685012 138 11632 3351 49 226 498.58 1 1 0 
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Table S.2: The top 200 type II compounds, their ranks and scores for each of the two 
models, and their consensus ranks 
Title DOLPHIN 
Rank 
DOLPHIN 
gscore 
MD Rank MD gscore Simple Sum 
Rank 
ZINC000096112051 1 -10.28 2 -11.098 1 
ZINC000004200873 2 -9.838 4 -11.017 2 
ZINC000096112254 6 -9.588 10 -10.703 3 
ZINC000096112048 13 -9.313 7 -10.794 4 
ZINC000096112049 27 -9.007 3 -11.023 5 
ZINC000096112349 21 -9.125 14 -10.599 6 
ZINC000008299930 17 -9.174 19 -10.487 7 
ZINC000096112052 39 -8.888 1 -11.244 8 
ZINC000096112343 12 -9.314 34 -10.319 9 
ZINC000096112199 24 -9.081 25 -10.435 10 
ZINC000004259649 37 -8.906 20 -10.486 11 
ZINC000096112247 56 -8.808 15 -10.598 12 
ZINC000096112042 29 -8.971 50 -10.224 13 
ZINC000096112276 64 -8.781 24 -10.444 14 
ZINC000096112378 9 -9.483 80 -10.064 15 
ZINC000096112245 11 -9.347 84 -10.053 16 
ZINC000096112255 48 -8.838 51 -10.215 17 
ZINC000004899492 57 -8.807 46 -10.244 18 
ZINC000004147673 84 -8.679 27 -10.409 19 
ZINC000004259418 108 -8.558 9 -10.741 20 
ZINC000004259703 80 -8.691 53 -10.204 21 
ZINC000004259576 72 -8.736 67 -10.127 22 
ZINC000096112324 96 -8.617 49 -10.224 23 
ZINC000096112392 26 -9.052 124 -9.908 24 
ZINC000096112354 91 -8.646 61 -10.152 25 
ZINC000096112383 116 -8.537 48 -10.225 26 
ZINC000096112075 90 -8.646 76 -10.072 27 
ZINC000096112040 92 -8.644 75 -10.076 28 
ZINC000008623925 158 -8.398 16 -10.578 29 
ZINC000008297322 181 -8.331 13 -10.605 30 
ZINC000096112290 169 -8.365 30 -10.337 31 
ZINC000096112074 15 -9.243 197 -9.677 32 
ZINC000096112358 135 -8.451 83 -10.053 33 
ZINC000003841754 141 -8.436 88 -10.033 34 
ZINC000004200863 195 -8.296 40 -10.271 35 
ZINC000005415248 234 -8.225 5 -10.958 36 
ZINC000096112357 19 -9.165 223 -9.613 37 
ZINC000008297285 189 -8.314 55 -10.196 38 
ZINC000096112259 236 -8.224 12 -10.649 39 
ZINC000004235417 231 -8.226 26 -10.428 40 
ZINC000096112291 229 -8.234 31 -10.332 41 
ZINC000004222877 205 -8.271 57 -10.174 42 
ZINC000096112257 240 -8.214 38 -10.279 43 
ZINC000096112517 183 -8.323 96 -10.003 44 
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ZINC000008254491 283 -8.144 8 -10.763 45 
ZINC000096112258 316 -8.08 21 -10.472 46 
ZINC000005398917 263 -8.179 77 -10.071 47 
ZINC000008623923 254 -8.201 92 -10.017 48 
ZINC000020464047 274 -8.158 73 -10.097 49 
ZINC000012602805 282 -8.144 89 -10.03 50 
ZINC000008635898 288 -8.138 87 -10.048 51 
ZINC000096112252 360 -8.013 43 -10.266 52 
ZINC000004571260 5 -9.615 413 -9.287 53 
ZINC000004235515 370 -8.002 71 -10.112 54 
ZINC000004200864 4 -9.623 457 -9.223 55 
ZINC000008635710 439 -7.912 42 -10.269 56 
ZINC000008623263 418 -7.935 74 -10.079 57 
ZINC000008297827 467 -7.865 45 -10.246 58 
ZINC000008299947 494 -7.838 18 -10.515 59 
ZINC000003842094 481 -7.852 56 -10.182 60 
ZINC000004200876 10 -9.377 580 -9.092 61 
ZINC000049169096 614 -7.745 11 -10.674 62 
ZINC000096112057 642 -7.715 62 -10.15 63 
ZINC000096112353 658 -7.701 52 -10.214 64 
ZINC000008623031 696 -7.667 58 -10.171 65 
ZINC000096112311 689 -7.672 81 -10.064 66 
ZINC000096112395 25 -9.074 859 -8.867 67 
ZINC000012489972 810 -7.597 79 -10.066 68 
ZINC000096112256 30 -8.957 132 -9.869 69 
ZINC000096112242 50 -8.824 128 -9.885 70 
ZINC000096112038 63 -8.794 118 -9.935 71 
ZINC000005396040 76 -8.718 107 -9.972 72 
ZINC000096112066 86 -8.655 104 -9.98 73 
ZINC000096112047 73 -8.734 126 -9.892 74 
ZINC000096112108 55 -8.809 145 -9.803 75 
ZINC000096112312 79 -8.699 122 -9.916 76 
ZINC000096112109 35 -8.918 169 -9.737 77 
ZINC000084711477 61 -8.797 160 -9.757 78 
ZINC000096112328 53 -8.815 209 -9.642 79 
ZINC000004270569 137 -8.446 134 -9.858 80 
ZINC000096112036 89 -8.646 189 -9.687 81 
ZINC000096112063 104 -8.584 178 -9.718 82 
ZINC000008635535 153 -8.407 141 -9.812 83 
ZINC000096112083 174 -8.35 137 -9.844 84 
ZINC000020464030 160 -8.397 153 -9.779 85 
ZINC000096112237 54 -8.812 260 -9.54 86 
ZINC000004147676 33 -8.926 294 -9.479 87 
ZINC000096112062 51 -8.822 276 -9.514 88 
ZINC000004235603 196 -8.293 138 -9.844 89 
ZINC000096112246 93 -8.635 242 -9.564 90 
ZINC000096112249 126 -8.499 224 -9.61 91 
ZINC000004259578 58 -8.806 299 -9.47 92 
 123 
 
ZINC000005434050 245 -8.209 114 -9.952 93 
ZINC000030879565 74 -8.728 297 -9.474 94 
ZINC000096112028 165 -8.374 218 -9.624 95 
ZINC000012529846 185 -8.322 200 -9.656 96 
ZINC000008300469 204 -8.274 185 -9.697 97 
ZINC000096112283 175 -8.35 216 -9.629 98 
ZINC000096112250 246 -8.208 147 -9.792 99 
ZINC000096112372 275 -8.156 130 -9.882 100 
ZINC000030879845 40 -8.883 371 -9.349 101 
ZINC000096112078 237 -8.222 181 -9.708 102 
ZINC000096112235 154 -8.407 270 -9.523 103 
ZINC000004259582 161 -8.393 265 -9.529 104 
ZINC000096112270 151 -8.411 278 -9.511 105 
ZINC000096112054 34 -8.925 401 -9.31 106 
ZINC000096112070 82 -8.683 355 -9.372 107 
ZINC000096112337 217 -8.258 228 -9.607 108 
ZINC000096112273 321 -8.075 125 -9.905 109 
ZINC000096112295 281 -8.145 167 -9.745 110 
ZINC000096112064 81 -8.691 382 -9.339 111 
ZINC000004222811 348 -8.031 116 -9.937 112 
ZINC000096112177 356 -8.016 112 -9.957 113 
ZINC000004259272 99 -8.609 373 -9.347 114 
ZINC000096112213 168 -8.366 309 -9.455 115 
ZINC000004259381 371 -8.002 109 -9.968 116 
ZINC000015673884 324 -8.07 157 -9.763 117 
ZINC000014779351 111 -8.55 372 -9.348 118 
ZINC000096112216 45 -8.852 441 -9.247 119 
ZINC000030879550 69 -8.757 419 -9.277 120 
ZINC000096112387 382 -7.986 111 -9.961 121 
ZINC000096269383 59 -8.802 438 -9.25 122 
ZINC000096112065 46 -8.848 455 -9.224 123 
ZINC000096112297 159 -8.398 343 -9.391 124 
ZINC000096112390 105 -8.583 405 -9.306 125 
ZINC000014610053 103 -8.592 416 -9.284 126 
ZINC000096112035 87 -8.65 435 -9.256 127 
ZINC000004259111 372 -8 152 -9.781 128 
ZINC000225407026 390 -7.968 148 -9.789 129 
ZINC000096112381 252 -8.204 311 -9.449 130 
ZINC000005433653 420 -7.931 150 -9.785 131 
ZINC000005399735 314 -8.092 263 -9.535 132 
ZINC000096112356 415 -7.937 164 -9.755 133 
ZINC000004259117 331 -8.06 258 -9.545 134 
ZINC000096112236 261 -8.183 331 -9.408 135 
ZINC000096112110 52 -8.82 547 -9.134 136 
ZINC000096112072 67 -8.761 535 -9.14 137 
ZINC000008300038 289 -8.138 316 -9.443 138 
ZINC000096112039 230 -8.23 376 -9.347 139 
ZINC000096112056 225 -8.245 391 -9.324 140 
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ZINC000003842061 187 -8.315 436 -9.254 141 
ZINC000008300622 408 -7.943 220 -9.618 142 
ZINC000096112319 248 -8.206 384 -9.339 143 
ZINC000012376462 479 -7.853 154 -9.777 144 
ZINC000004235426 384 -7.981 252 -9.551 145 
ZINC000096112344 339 -8.049 304 -9.466 146 
ZINC000014651078 399 -7.96 248 -9.554 147 
ZINC000001095821 62 -8.795 589 -9.086 148 
ZINC000004235821 387 -7.974 269 -9.524 149 
ZINC000006017925 115 -8.542 542 -9.136 150 
ZINC000096112221 247 -8.208 410 -9.293 151 
ZINC000096112239 346 -8.034 315 -9.444 152 
ZINC000096112300 83 -8.682 582 -9.09 153 
ZINC000096112298 163 -8.381 503 -9.182 154 
ZINC000014779271 107 -8.558 561 -9.116 155 
ZINC000096112107 94 -8.633 575 -9.097 156 
ZINC000096112389 249 -8.206 425 -9.272 157 
ZINC000096112377 394 -7.965 281 -9.509 158 
ZINC000001588038 256 -8.197 424 -9.273 159 
ZINC000096112329 510 -7.826 174 -9.722 160 
ZINC000004222862 504 -7.831 184 -9.7 161 
ZINC000008635858 556 -7.791 136 -9.854 162 
ZINC000005412197 350 -8.024 359 -9.366 163 
ZINC000096112041 120 -8.529 590 -9.086 164 
ZINC000096112369 398 -7.96 312 -9.447 165 
ZINC000004293351 308 -8.108 404 -9.307 166 
ZINC000096112058 486 -7.847 232 -9.591 167 
ZINC000096112323 610 -7.747 108 -9.971 168 
ZINC000096112371 238 -8.218 489 -9.196 169 
ZINC000008299933 359 -8.013 369 -9.353 170 
ZINC000096112393 208 -8.27 525 -9.159 171 
ZINC000096112069 85 -8.661 653 -9.034 172 
ZINC000096112385 307 -8.11 447 -9.238 173 
ZINC000004235420 226 -8.242 540 -9.137 174 
ZINC000096112374 664 -7.699 102 -9.984 175 
ZINC000096112292 511 -7.825 264 -9.53 176 
ZINC000096112178 315 -8.083 461 -9.217 177 
ZINC000096296996 227 -8.237 553 -9.124 178 
ZINC000008635362 468 -7.864 323 -9.422 179 
ZINC000096112341 417 -7.935 379 -9.345 180 
ZINC000096112026 118 -8.532 680 -9.009 181 
ZINC000096112282 285 -8.14 519 -9.165 182 
ZINC000012603333 596 -7.76 208 -9.643 183 
ZINC000096112332 155 -8.402 651 -9.035 184 
ZINC000096112034 150 -8.412 657 -9.027 185 
ZINC000096112243 616 -7.744 194 -9.682 186 
ZINC000004222865 520 -7.82 293 -9.483 187 
ZINC000096112251 77 -8.717 739 -8.955 188 
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ZINC000030881843 647 -7.711 173 -9.723 189 
ZINC000096112315 326 -8.065 500 -9.185 190 
ZINC000096112386 342 -8.038 490 -9.195 191 
ZINC000008623875 582 -7.767 255 -9.547 192 
ZINC000008623222 441 -7.912 398 -9.312 193 
ZINC000005410189 720 -7.655 140 -9.822 194 
ZINC000015672358 255 -8.2 608 -9.077 195 
ZINC000030881268 555 -7.795 328 -9.416 196 
ZINC000008635918 681 -7.682 202 -9.654 197 
ZINC000096269328 216 -8.259 669 -9.016 198 
ZINC000096112229 612 -7.746 273 -9.515 199 
 
 
